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ABSTRACT
Interaction between Adrenergic and Nitric Oxide-releasing
Nerves in Cerebral Arteries
by
Emmanuel Ngu Mbaku
Doctor of Philosophy, Graduate Program in Pharmacology
Loma Linda Unviersity, June 2003
Dr. John Buchholz, Chairperson

Of all body tissues, the brain is the least tolerant of ischemia so much that
interruption of cerebral blood flow by 5 sec can cause syncope, with irreversible
tissue damage if the ischemia last a few minutes. In this respect, the body has an
imperative duty of ensuring constant and adequate blood supply to the brain. It
does so through a series of intrinsic and extrinsic control factors of which
adrenergic and nitric oxide-releasing nerves are components. My research
examined the interaction between these two nerve-types with emphasis on the
mechanisms involved as well as on changes in their functions as the animal
adapts to stress such as chronic hypoxia.
An overview of endogenous NO which is synthesized by nNOS, reveals
that NO exhibits numerous and wide spread interactions in the nervous system
with implications in disease conditions such as Multiple Sclerosis, Schizophrenia,
Parkinson’s and Alzheimer’s diseases. On the other hand, beneficial effects of
NO include a role in synaptic plasticity and modulation of sympathetic nerve
activity in cerebral arteries with potential to modulate cerebral circulation.
This thesis provides evidence supporting the hypothesis that adrenergic
and nNOS nerves co-exist within cerebral arteries and strongly suggest an
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interaction between these two neuron types such that NO released from the
nNOS nerves serves to facilitate NE released from the adjacent adrenergic
nerves. In addition, evidence in this thesis also show that in the course of
adapting to stress such as chronic high altitude hypoxia, the ability of nNOS
nerves to modulate adrenergic function is lost. This lost of nNOS nerve function
is due at least in part to a decline in the expression of nNOS protein.
The mechanism by which NO modulates adrenergic nerve function has
been proposed to involve a cascade of reactions leading to the mobilization of
intracellular free calcium within adrenergic nerve terminals. Recall that the
release of neurotransmitter such as NE from stored vesicles requires an increase
in [Ca2+]i. This thesis provides data in support of the hypothesis that the NO/
cGMP-dependent protein kinase -1 pathway controls intracellular calcium
mobilization which could underlie the mechanism of NO modulation of adrenergic
nerve function in cerebral arteries. However, it remains to be ascertained
whether the NO/cGMP-dependent protein kinase-induced mobilization of [Ca2+]l
is mediated via cADP ribose.

xv

INTRODUCTION
AN OVERVIEW OF NITRIC OXIDE

Characteristics and Biosynthesis of Nitric Oxide
Nitric oxide (NO) is an odorless, colorless diatomic compound that exists
as a gas at room temperature. The molecular orbital structure of NO is such that
it has a single electron in the 7t2p* molecular orbital (a high-energy anti-bonding
molecular orbital) which makes it paramagnetic and highly reactive (Zumdahl
1989). Nitric Oxide is a very small, lipophillic, readily diffusible, and chemically
unstable molecule with a very short chemical half-life (1to 5 seconds) and would
typically produce effects immediately and locally (Ignarro, 1991). However, some
endogenous molecules can regulate NO availability and could confer a specificity
of action to the widely diffusible messenger NO. For example, iron-sulfurcenters, heme proteins especially hemoglobin and sulfhydryl species (thiols) can
package NO and could act as scavengers and/or transporters, prolonging its life
and targeting its delivery to specific effecters (Do et al., 1996). Once released
following synthesis, NO diffuses out of the cell and interacts with target
molecules (see figure 1 below). Several reaction pathways for NO have been
identified (Ignarro, 1990; Blough and Zafiriou, 1985). These include the following:
(1) The guanylyl cyclase /cGMP pathway
(2) Complexing with iron-sulfur centers (Fe-S-NO)
(3) Reactivity with oxygen to yield NO2 gas or NO2' in solution:
2NO + 02

2N02'
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(4) Reactivity with superoxide anion (02') to yield the unstable intermediate
peroxynitrite anion ( OONO), which rearranges to from N03~.
NO + 02- -> OONO -> N03'
(5) Reactivity with ozone (03) to yield an activated or high-energy state N02: The
activated N02 can be readily detected by chemiluminescence. This is the
principle used by the Siever 270 B NO analyzer.
(6) Reactivity with oxyhemoglobin to yield methemoglobin and inorganic nitrate
according to the overall reaction
Hb02 + NO

methHb + 'OONO; and "OONO -> NOT

(7) Reactivity with sulfhydryl groups (R-SH) to yield S-nitrosothiols (R-SNO). An
example of this is the attack on cysteine to produce S-nitrosocysteine.
R-SH + NO -> R-SNO + H+, and R-SH + N02' -> R- SNO + H20
(8) Other nitrosation reactions involving NO include the formation of Nnitrosamines.
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A - NO synthesis in a neuron

B - Target cell for NO

NMDA Receptor
Ca++
influx

Activated nNOS
Guanylyl cyclase
' Fe-S center
Super Oxide
L- Arginine

L - Citruilline

yFhO /Hemoglobin
\

Monomers of inactivated
nNOS linked by a
Calmodulin molecule

Figure 1: This figure illustrates the biosynthesis of NO, as catalyzed by a typical
calcium-dependent isoform of NOS - for instance nNOS. The double-shafted
blue arrow indicates the direction of diffusion of NO from the host (yellow) cell, to
the target (green) cell. Orange arrows point at targets in the various modes of
action of NO.
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Although NO is one of the simplest molecules in nature it is synthesized
by complex enzymatic processes. In vitro experiments on reactions involving the
azide anion (N3~), hydroxylamine (NH2OH), and hydrazine (NH2NH2) in which N3'
and NH2OH undergo oxidation to produce NO in a complex enzymatic reaction
catalyzed by catalase have been reported (Keilin and Hartree, 1954; Nicholls,
1964). A similar reaction with hydrazine requires the addition of peroxide.
However, with no reports since then, of any in vivo reactions of this nature, the
azide-hydroxylamine-catalase pathway or the hydrazine-peroxide-catalase
reaction pathway seemed to have little physiological significance with respect to
NO biosynthesis. Whereas in the more recently described enzymatic reaction
discussed below (and which is by far more physiologically involving) L-arginine is
converted to NO and citrulline (Hibbs et al., 1998).
In this synthetic pathway (involving L-arginine), NO is a co-product of Lcitrulline, issuing from the oxidation of L-arginine. Based on knowledge of the
bioavailability of NO, it would appear that without the catalytic support of nitric
oxide synthase, the reaction kinetics of such an oxidation would be too slow (if
not impossible) to produce NO in amounts that are physiologically significant.
Nonetheless, enzyme-independent production of NO in which administered Larginine analogs such as L-NAME, L-NA, L-NMMA, and L-NIO - are significant
sources has been reported (Moroz et al., 1998).
Nitric Oxide Synthase (NOS) is a homodimeric flavo-hemoprotein that
catalyses the 5-electron oxidation of L-arginine to NO and L-citrulline (Klatt et al.,
1992). This enzymatic reaction is similar to that catalyzed by the cytochrome
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P450 system, and requires numerous cofactors including calmodulin, NADPH,
flavins, heme and tetrahydrobiopterine (White and Marietta, 1992; Stuehrand
Ikeda-Saito, 1992; McMillan et al., 1992). NOS exist in three different isoforms eNOS, nNOS and the iNOS. Endothelial and neuronal NOS isoforms are
constitutively present in select cell types and are activated by intracellular
calcium, which binds to calmodulin and promotes activation of the enzyme. The
inducible NOS on the other hand, is expressed in many cell types but only after
induction by cytokines and/or endotoxin (Shahidi and Kilbourn, 1998) and is
regulated at the transcriptional level (Garvey et al, 1994). This isoform is
independent of calcium and calmodulin although it still requires NADPH, FAD
FMN, and BH4 for full activity (Moncada et al., 1991; Nathan, 1992). This iNOS
isoform comes with calmodulin already tightly bound as a subunit (Cho et al.
1992) and therefore, requires no increase of intracellular calcium for enzyme
activation - it is already activated as it is being synthesized from its mRNA.
Certain circumstances are known to provoke the induction of iNOS - and these
include; vascular injury or inflammation (Schini et al., 1994; Busse and Mulsch,
1990), infection and/or endotoxins (Kilbourn and Belloni, 1990), and diabetes
mellitus (Corbett et al., 1993, 1993), and cancer (Kilbourn et al., 1984; Li, 1991).

Regulation and Modulation of Physiological Nitric Oxide Production
All three mammalian isoforms of NOS must bind calmodulin for enzyme
activity. Only iNOS does so at low levels of free Ca2+ in resting cells (Ruan et al.,
1996). Constitutive NOS isoforms (eNOS and nNOS) are activated by a complex
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process that requires an increase in intracellular free calcium concentration,
[Ca2+]i as well as phosphorylation at specific sites of its domains (Fleming and
Busse, 2003; Fleming et al., 2001; Dimmeler et al., 1999; Wu, 2002, and Nakane
M.,et al..1991). Once bound to four calcium ions, following an increase in
intracellular calcium, the activated calmodulin takes up position at its binding site
- a hinge region between the two domains of NOS. Binding of the
Ca27calmodulin complex promotes association of monomeric NOS oxygenase
domain resulting in dimmerization, which gives rise to a configuration capable of
NO synthesis (Hellermann and Solomonson, 1997). See Figure 2 below for
details. Enzyme activity (NO biosynthesis) is regulated at several levels including
NO exertion of negative feedback inhibition (Abu-Soud et al, 1995; Rengasamy
and Johns, 1993; Griscavage et al., 1994), substrate availability (Presta et al.,
1997; Matsuoka et al., 1994), and NOS phosphorylation & dephosphorylation
(Fleming and Busse, 2003; Fleming et al, 2001; Dimmeler et al., 1999; Nakane et.
al., 1991).
Unlike nNOS and eNOS, the cytokine inducible NOS (iNOS) exhibits a
slightly different mechanism. As mentioned above this isoform does not require
an increase in intracellular calcium concentration for activation. NO production is
initiated as soon as the synthesis of iNOS is complete (Chao et al., 1992). It is
not yet clear how the cell avoids suicidal amounts of NO synthesis due to iNOS
expression. Nevertheless, it has been shown that NO exerts a negative feed
back inhibition on NOS (Buga et al., 1993; Rogers and Ignarro, 1992,
Rengasamy, and Johns, 1993, and Griscavage J.M., et al 1994).
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Inactive
Conformation

Active
Conformation

Dyes
Or
Cyt c
♦

HEME
Arg

HEME
*

FM

bh4

FAD

FMN

O

Arg

FADNADP

NO

NADPH

SjMj
Oxidase
Domain

CAM
Binding Site

\
Reductase
Domain

Superoxide

o2

Activated
Calmodulin

Figure 2: Role of Calmodulin (CAM) in aligning the oxygenase (N-terminal) (left)
and the reductase (C-terminal) (right) domains of nNOS. In this figure, solid
arrows indicate electron flow. Calmodulin (CAM) with four associated Ca2+ atoms
binds to a “hinge” region aligning the domains and allowing electron transfer from
FMN to heme.
In the absence of Ca2+/calmodulin, electrons flow more slowly to other receptors
such as cytochrome c (cytc). In the absence of arginine, activated (O-O) can
dissociate from heme as superoxide O2' (dashed arrow).
Arg = L-arginine, BH4 = tetrahydrobiopterine, FMN = flavin mononucleotide, FAD
= flavin adenine dinuclotide, NADPFI = nicotine adenine Dinuclotide phosphate reduced, and Ctl. = citrulline.
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Pharmacological and Physiological Significance of Nitric Oxide
The physiological and pharmacological interactions of NO with other
systems are numerous and wide spread and can be beneficial, neutral or toxic to
the target tissues. NO elicits the following physiological activities: vasodilation
and anti-platelet aggregation effects (Schlossmann et al., 2003; Beghetti et al.
2003), and it has an active role in memory storage. NO is also linked to the
inhibition of the immune system through the suppression of lymphocytes and / or
T-cells proliferation (Ahvazi et al., 1995; Albina and Henry Jr., 1991; Sternberg
and McGuigan, 1992). In diabetes, NO has a role in the mediation of insulin
release (Schneid et al., 2003, Schneid et al., 2003, and Laychock et al., 1991)
and in cerebrovasculature NO modulates sympathetic nerve activity and
possesses neurotransmitter functions (Mbaku et al., 2000, and Mbaku et al., 2003). On the other hand, pathophysiological actions of NO include septic shock
- in which cytokines like interleukin-1, or tumor necrosis factor alpha, induce a
separate and high out put form of NOS that synthesizes NO in both endothelial
and smooth muscle cells causing profound vasorelaxation (Kuhl and Rosen,
1998; Vallance and Moncada, 1993; Lorente et al., 1997). Further more, NO
mediates acute and chronic inflammation and can destroy invading bacteria
(Lemerse et al., 1997). Apoptotic activities of NO have also been reported - in
which NO initiates and mediate cell death such as in allograft rejections
(Szabolcs et al., 1996). Lastly NO has been implicated in Parkinson’s, Alzheimer
diseases, and tumor cells suppression (Simeone et al., 2002, Kim et al., 2001).
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The constitutive isoforms of NOS i.e. endothelial and neuronal NOS are
responsible for the biosynthesis of small but physiologically important amounts of
NO. Such small amounts of NO are completely non-cytotoxic. An inducible
isoform of NOS, which is a distinct gene product from the constitutive isoforms, is
responsible for high output production of NO (Vallance and Moncada 1993).
Generation of large amounts of NO is associated with cytotoxicity and
pathophysiology. A few examples include (a) the induction of NOS in vascular
smooth muscles resulting in profound vasorelaxation and hypotension, all of
which are characteristics of endotoxin shock mentioned above (Thiemermann,
1997). (b) The induction of NOS in brain microglia and astrocytes resulting in
production of large amounts of NO which permeate oligodendrocytes leading to
impaired myelin production, the hallmark feature of multiple sclerosis (Mitrovic et
al.,1994). (c) The induction of NOS in joints tissues, resulting in acute and
chronic inflammation, a characteristic sign of arthritic diseases (Vuolteenaho et
al., 2003; Borderie et al., 1999; Ishiuchi et al., 1999).
NO is thought to have at least four main functions in the nervous system
particularly the brain: (a) as vasorelaxant with an important role in modulating
cerebrovascular tone and controlling blood flow: (b) As a neurotransmitter released upon perivascular electrical stimulation (Mbaku et al., 2000). (c) As a
cytotoxin that may contribute to neuronal cell death and (d) as a neuroprotective
agent that may decrease the toxic NMDA-mediated influx of Ca2+ ions (Manzoni
O., and Bockaert J., 1993, Tanaka T., et al 1993)
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Detrimental Activities of Nitric Oxide involving the Nervous System
There are many studies suggesting that NO may play a diverse role as
both a possible cause and mediator of various neuronal pathologies. In
cerebrovasculature, the associating ischemic hypoxia causes glutamate release
accompanied by inhibition of its removal, leading to NMDA receptor over
activation and excess Ca2+ influx, which in turn activates NO synthesis (Dawson
1994; Zhang and Snyder, 1995). A similar NMDA receptor and NO-mediated
excitotoxicity mechanism has been described in Huntington’s disease (Meldrum
and Garthwaite, 1990). In Acquired Immune Deficiency Syndrome, the human
immunodeficiency virus appears to induce NO production by iNOS through the
glutamatergic pathway (Adamson et al., 1999, Corasaniti et al., 1998).
NO exerts its neurotoxic effects via several mechanisms. Nitric Oxide is a
free radical and can combine with superoxide anions to form peroxynitrite,
another highly destructive radical moiety (Eliasson et al., 1999). The resultant
reactive oxygen species can induce significant oxidative stress that causes lipid
peroxidation and produces functional alterations in proteins and DNA, eventually
leading to neuronal death (Beckman et al., 1994). Nitric Oxide can also cause
nitrosylation in a variety of proteins. These include PKC and glyceraldehydes-3
phosphate dehydrogenase (GADPH), thereby inhibiting phosphorylation and the
glycolytic pathway, respectively (Zhang and Snyder, 1992 and 1993).
Furthermore, NO or peroxynitrite can impair glycolysis and subsequent cellular
energy production by potentiating ADP-ribosylation of GADPH (Zhang and
Snyder, 1992, 1993). NO by damaging DNA, could also lead to poly ADP-ribose
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polymerase over-activation, causing neuronal ATP depletion and death (Ha and
Snyder, 1999; Zhang and Steiner 1995). Another mechanism by which NO
affects mitochondrial energy production is via its ability to bind aconitase as well
as complex 1, 2, and 3, resulting in glycolysis and electron transport chain
inhibition, respectively (Dawson et al., 1992; Gross and Wolsin, 1995). Hence,
increasing NO production can lead to cellular toxicity and death via a variety of
pathways and mechanisms. The discussion below focuses on Parkinson’s
disease (PD), multiple sclerosis (MS) and Schizophrenia.

Parkinson’s Disease (PD)
The degeneration of dopaminergic (DA) neurons particularly the DA
neuron population within the substantial nigra is a hallmark of Parkinson’s
disease. The primary cause of cell death underlying PD is unknown. However, a
number of hypotheses (which are not mutually exclusive) have been postulated
including free radicals, iron accumulation, neurotoxins, defective mitochondria
function and genetic predisposition. NO, a suspect in free radical mediated cell
death, and as a possible neurotoxin is now thought to be involved in the defective
mitochondria function particularly the complex 1 inhibition seen with PD (Shergill
et al., 1996).
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Mitochondria Complex 1
The mitochondria NADH dehydrogenase (Complex 1) activity has been
reported to decline in the substantia nigra of the PD brain (Schapira, 1989). This
effect appears to be anatomically specific to the substantia nigra and disease
specific to PD (Schapira et al., 1990). Recent studies show that the primary
target of NO inhibition of cell respiration is the mitochondria cytochrome c
oxidase, the inhibition of which has been suggested to be a mediator for the
irreversible loss of complex-1 function in a chemical model of PD. (Schapira, et
al., 1990; Cleeter et al., 1994, and Brown and Cooper, 1994). Nevertheless, it is
important to note that the inhibition of cytochrome c oxidase is required for the
irreversible loss of Complex 1 function in a chemical model of PD (Cleeter et al.
1992). These data suggest a direct link between NO and the cytochrome c
oxidase inhibition associated with PD.
In an experiment using Electron Paramagnetic Resonance (EPR)
spectroscopy to investigate Complex 1 activity in human substantia nigra and
globus pallidus both in healthy controls and PD models, it was shown that a
significant increase occurred in the heme-NO concentration in PD substantia
nigra but not in the control. This serves as evidence that excess NO production
occurs in PD substantia nigra and may be involved in the accompanying neuron
degeneration (Shergill et al., 1996).
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MPTP - induced Parkinsonism
In humans and nonhuman primates, 1-methyl 4-phenyl 1,2,5,6
tetrahydropyhdine (MPTP) produces clinical, biochemical, and neuropathologic
changes analogous to those observed in idiopathic Parkinson’s disease. In the
brain, MPTP is metabolized by monoamine oxidase B (MAOB) to 1-methyl-4phenylpyridinium ion (MPP+), (Tipton K.F., and Singer T.P., 1993). MPP+ is
selectively taken up by the high affinity dopamine and norepinephrine uptake
systems and is subsequently accumulated within the mitochondria of
dopaminergic neurons of the substantia nigra. Here, it disrupts oxidative
phosphorylation by inhibiting Complex 1 of the mitochondria electron transport
system (Gluck et al., 1994). The interruption of oxidative phosphorylation results
in decrease levels of ATP (Chan et al.,1991), which may lead to partial neuronal
depolarization and release of transmitters (glutamate) that activates NMDA
receptors resulting in excitotoxic neuronal cell death (Beal, 1992). The
mechanism of such excitotoxicity is not yet clear but it has been attributed at
least in parts to high Ca2+ influx.
Thus, a question that arises from this observation is that what role does
NO play in this? One possibility is that entry of Ca2+ through activated NMDA
receptor channels into cells activates the Ca27Calmodulin - dependent neuronal
isoform of NOS. Studies in dissociated cell cultures showed that NOS inhibitors
effectively blocked NMDA - induced cell death (Dawson et al., 1991). In addition
increased production of NO may react with superoxides (0'2) to generate cell
toxic peroxynitrites (Beckman et al., 1990). Peroxynitrites, in addition to nitration
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of tyrosine residues on proteins (Schulz et al., 1995; Robert et al., 1998),
production of hydroxyl radicals and oxidative stress (Beckman et al.,1990, and
Bredt, 1999), are also known to destroy DNA, (Love, 1999), oxidize and
inactivate norepinephrine - thereby limiting successful treatment of hypotension
in septic shock (Takakura et al., 2003)
In a study done by Jorg B Schulz the involvement of NO in MPTP toxicity
was examined. It was shown that the nNOS selective inhibitor 7 - Nitroindazole
(7-NI) blocked the dopaminergic neurotoxicity seen in mice after systemic
administration of MPTP. They also showed that MPTP toxicity causes an
increase in the content of nitrotyrosine and that treatment with NOS inhibitors
such as 7-NI, decreases the production of nitrotyrosine (Schulz J.B et al 1995).
Taken together, these studies suggest that in the MPTP model of PD there is a
cascade of events including calcium overload leading to excess NO production
that may be relevant to a wide spread neurotoxicity.

Alzheimer’s Disease (AD)
Alzheimer disease is a complex syndrome - judging from scientific
information that has been obtained from years and years of research. An early
stage in the pathophysiology of AD is characterized by the formation in specific
brain regions (entohrinal cortex and the hippocampus), of a protein - reach
“mass” referred to as p- amyloid plaques and (AP) and neurofibrillary tangles
(NTF). Several mechanisms have been proposed but none of which can
precisely explain the disease etiology. Nonetheless, most of these hypotheses
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have logical theories pertaining to the disease state and could be relevant to AD
etiology. The resulting clinical symptoms and neuropathology observed with AD
are most likely secondary to an interplay of multiple pathogenetic components
with diverse mechanisms (Law et al 2001; de la Torre J 2002). The ‘cholinergic
hypothesis’ is perhaps the most extensively studied amongst all the hypotheses
that attempt to describe AD pathogenesis. Even then, at best, cholinergic drugs
(which are still the only pharmacological treatment currently available for
cognitive AD symptoms (Cummings et al., 1998; Davis et al., 1992; Rockwood et
al. 1997 and Rogers, 1998)) have been modest and variable with primary
efficacy being only symptom-progression-slowing (Bodic, et al., 1997, Molloy et
al 1991, and Gauthier et al., 1990). Therefore, there is still a long way to go.
The involvement of NO in a number of neuronal disorders is well
established. In recent years, researchers have begun to recognize and to explore
the putative link between NO and AD (Dorheim et al., 1994, and Norris et al
1996). Although existing evidence regarding their association is not abundant
emerging data are showing AD-related changes in the NOS system and it
appears that NO could be related to many of the AD pathological mechanisms.
Furthermore, the relationship between NO and AD may not be limited to NOmediated neurotoxicity, the potential neuroprotective properties of NO should be
considered as well. After all, NO can be either neurotoxic or neuroprotective
depending on conditions such as its concentration or the redox state of the tissue
(Lipton, et al., 1993; Wink et al., 1993; Fagi et al., 1995; Lei et al., 1992).
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In the central nervous system nNOS, has extensive distribution in the
cortex, hippocampus and cerebellum. To date, data regarding the changes of
NOS in AD are highly inconsistent. For instance, some reports indicate that there
is excess NO production in AD substantia nigra and cerebral micro vessels
(Benzing et al., 1995, and Dorheim et al., 1994) respectively. Others suggest that
NO production is in excess during the early stages of AD but then declines as
neuron degeneration progress (Tohgi H., et al 1998). Yet some researchers
believe that NO production show significant decrease in the temporal lobe
(Gargiulo, et al., 2000). Moreover, there are reports suggesting selective
degeneration of nNOS nerve population in the frontal cortex and hippocampus of
AD (Norris et al., 1996; and Thorns V., et al., 1998). Whereas some other set of
data suggest that nNOS nerves are selectively preserved in AD (Hyman et al.,
1992; and Tao et al 1999). Still other data indicate that in AD, nNOS population
decreased significantly in frontal cortex, but increased significantly in the
hippocampus when compared to healthy controls (Yew et al., 1999). The reason
for these discrepancies could be secondary at least in part to the variability in
tissue labeling and fixation methods. More studies would definitely be helpful to
clarify this controversy.
The ability of NO to exert cellular damage due to its reactive oxidative
properties is perhaps the primary neurotoxic mechanism - so that any stimulus
capable of initiating an overproduction of NO will likely cause neuronal damage.
For example, the glutamatergic excitotoxicity mentioned above in which
excessive glutamate-mediated activation of the NMDA and / or AMPA / kinase

16

receptors lead to pathological Ca2+ influx (Choi, 1988). The resulting increase in
intra-neuronal Ca2+ concentration induces the activation of a variety of neurotoxic
compounds - including NOS (and subsequently high amounts of NO), that
compromises neuronal viability. Although no increase in glutamate levels are
seen in AD (Carlson M.D., et al 1993, Hyman B.T., et al 1987, Masliah et al.,
1996), such excitotoxicity mechanism can occur in the presence of physiological
glutamate concentration if additional pathological factors are present. This is
likely, particularly in highly susceptible areas such as the parahypocampal and
entorhinal cortex (Arias et al., 1998; Gray and Patel, 1995; Greenamyre 1991;
Guo et al., 1999).
A(3 is a well characterized source of NO over-production in AD, and has
been shown to have synergistic action with glutamate to induce neuronal
damage via an NO induction pathway (Aksenove et al 1995; Le et al 1995; Noda
et al., 1999; Yang, 1998). Resent evidence indicates that in early stages of AD,
reactive astrocytes (Wallace et al.1997), and microglia (Akama et al., 1998; Boje
and Arora, 1992; Colton et al., 1994; George-Hyslop et al., 1987; Goodwin et al.,
1997; Rossi and Bianchini, 1996; Tanaka et al 1997; and Wallace et al., 1997),
move in and surround even primitive plaques that do not yet contain any
degenerative neurites. Studies done using NADPH diaphorase staining suggests
that these reactive astrocytes secrete amongst other things, high amounts of NO
in the vicinity of the plaques. In addition, activated microglia produces TNF-a,
which also potentiates NO production (Kroncke et al., 1995). The resultant
increased NO production by these different means would most likely lead to
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increased free radical concentration and possibly cell death. In the AD brain, both
NO and peroxynitrite-mediated cell death have been observed (Chabrier et al.,
1999; Good et al., 1996; Koppal et al., 1999; and Van Dyke, 1997).
Ca2+ homeostasis dysfunction is another mechanism that supports the link
between NO and AD, since Ca2+ is a primary regulator of nNOS activation.
Various studies have shown that Ap can disrupt calcium homeostasis (Hartman
H., et al., 1993; and Mattson et al., 1991). Slow progressive increases in
intracellular Ca2+ concentration in cultured human and animal cortical and
hippocampal neurons upon Ap exposure have been observed (Mattson et al.,
1992; and Mattson et al., 1993). Furthermore, Ap pretreatment enhanced the
effects of glutamate and membrane depolarization on intracellular Ca2+
concentration (Hartman et al., 1993; Mattson et al., 1992; and Mattson et al.
1993). One of the outcomes of elevated intracellular calcium concentration is the
increase production of NO by nNOS, which may exert neurotoxic effects. Ap may ’
also act in similar manner in AD associated amyloid angiopathy, thereby leading
to eNOS activation (Bredt et al., 1990; and Sinha et al., 1999)
Excess oxidative stress is common in AD where there are increased lipids,
proteins and DNA oxidation in the AD brain (Lyras et al., 1997, McIntosh et al.,
1997, and Mullaart et al., 1990). Although NO may not be the only perpetrator in
causing oxidative damage in AD, its involvement appear to be significant, since
multiple pathological factors in AD have been shown to affect NOS expression. In
addition to the direct cellular damage caused by excess oxidative stress,
mitochondria dysfunction, which has been implicated in AD, is a ‘reactive oxygen
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species’-mediated pathological outcome. The ability of NO to cause mitochondria
damage as a free radical and by producing peroxynitrite is well-documented
(Brown, 1999, and Zweig et al., 1989).
NO also participates in inflammatory processes by activating
cyclooxygenase II (COX-2), which in turns activate the arachidonic acid cascade
that is known to be pro-inflammatory (Bauer et al 1997; and del Zoppo et al.,
2000). In accord with this observation is the fact that COX-2 expression has been
shown to be up regulated in AD (Ho et al., 1999, and Tocco et al., 1997). As
mentioned above, cholinergic deficit is one of the most prominent
neuropathological features of AD. NADPH diaphorase labeling has demonstrated
co-localization of NOS-positive neurons with cholinergic neurons (by ChAT
labeling) in basal forebrain nuclei (Begley et al., 1999; Bredt et al., 1990). Studies
have shown that NO modulates acetylcholine release (Ikarashi et al 1998;
Leonard and Lydic, 1995, and Vaucher et al., 1997). Caution! A direct link
between NO-mediated modulation of cholinergic release and AD
pathophysiology has so far not been established. However, the presence of
NOS-positive neurons in close proximity to cholinergic neurons may perhaps be
related to the selective vulnerability of the basal fore brain cholinergic system
secondary to NO neurotoxicity.
NO has been shown to be a player in apoptotic processes with low
concentrations being anti apoptotic and higher concentrations being pro
apoptotic (Dimmeler and Zeiher, 1997; Estevez et al., 1995; and Kim et al.
1997). In either case the mechanism by which NO influences apoptosis appear to
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involve caspases 1 and 3 (Matsuzaki et al., 1999, Tamatani et al., 1998, and
Tringali et al., 1999). Since high NO production occur in AD brain, it is possible
that NO may have a role in the apoptotic process in AD. Although apoptosis
appear to be limited in the AD brain, the relationship between NO and AD in this
regard should not and cannot be overlooked.
Ap and NFT are two important AD markers. There is evidence that NO
may have a role in the development of Ap and NFT. Elevated p21ras expression
in the AD brain has been implicated in the formation of Ap and NFT. Since NO is
an activator of p21ras (Dawson et al., 1998, Lander et al., 1995, Luth etal., 2000
and Yun et al., 1998), and co-localization of nNOS and p21ras in NFT-containing
pyramidal neurons has been reported (Luth et al., 2000), then activation of
p21ras by NO could trigger Ap and NFT formation as well as further inducing
nNOS expression thereby rendering the neurons in a vicious cycle of neuronal
degeneration. Overall, AD is a complex mental disorder with multiple pathological
mechanisms. Flowever, in recent years there has been growing evidence that NO
(synthesized by nNOS and iNOS) may be central to many of AD pathogenic
pathways.

Multiple Sclerosis
Multiple sclerosis is characterized not only by wide spread loss of myelin
from nerve fibers, but also by widespread inflammation in the central and
peripheral nervous system respectively. Although demyelination alone is
sufficient to block conduction and thereby causing symptoms of the disease,
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there is increasing evidence that the inflammation may also contribute
significantly to the conduction block although the mechanism is yet not
understood. The studies cited below would suggest that NO plays both a role in
the inflammatory process of multiple sclerosis and excessive amounts of NO may
also play a role in conduction of myelinated neurons.
Nitric Oxide is an important inflammatory mediator, and its concentration is
elevated within the central nervous system in multiple sclerosis (Yamashita et al.,
1997, and Peltola, 2001). When experimentally applied to tissues using Nitric
Oxide donors, the results show that such compounds cause reversible
conduction block in both normal and demyelinated axons of the central and
peripheral nervous systems. Notably, conductions in demyelinated and early
remyelinated axons are particularly sensitive to block by Nitric Oxide, so that at
lower concentrations, including those expected at sites of inflammation,
demyelinated axons are selectively affected (Redford et al. 1997). These data
suggest that the inflammation associated with multiple sclerosis may directly
cause symptoms via Nitric Oxide release. Moreover, the inhibition of such NO
release may be a new therapeutic avenue for multiple sclerosis and other
demyelination diseases.

Inhibition of Dopamine (DA) and Glutamate (Glu) Reuptake
Glutamate is an excitatory amino acid neurotransmitter in the brain and is
involved in learning and memory (Nicoll et al., 1998). Glutamate acting on the
NMDA receptors causes an increase in intracellular calcium thereby stimulating
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Schizophrenia (Dementia)
Unlike Alzheimer’s disease (in which senile degeneration of neurons is
characteristic), patients with schizophrenia have developmental abnormalities of
brain structures and function which include a diffuse neuronal loss most marked
in the temporal lobe as well as alterations in the glutamate neurotransmitter
system (Akbarian et al., 1993; Kerwin and Murray, 1992; Konradi and Heckers
2003). Dementia has a diverse nature of clinical symptoms and a number of
hypotheses have been suggested to explain its etiology - ranging from genetic
predisposition (Harrison and Owen 2003, Walker et al 2002), to environmental
abnormalities such as obstetric complications (Walker et al., 2002).
The role of nitric oxide in the pathophysiology of Schizophrenia has been
suggested and all the evidence put together, suggest that NO might have
multiple effects on this mental disease condition. For example, NO may
contribute to the oxidative stress common in Schizophrenia. This believe is
supported by the existence of significant increases in the concentrations of the
lipid peroxidation product -malondialdehyde (MDA) and the antioxidant enzymes
- supper oxide dismutase (SOD) and glutathione peroxidase (GSH-Px) (Kuloglu
et al., 2002, Akyol., et al 2002) in plasma from schizophrenics compared to
controls. Moreover, similar increases in NO/NOS activity (Das et al., 1995) and
an imbalance in NOS/Arginase activities (decrease in arginase activity) with
significantly elevated levels of plasma nitrite (Yanik et al., 2003) strongly suggest
NO involvement. In bipolar disorder, a mental defect similar to schizophrenia,
elevated NO and oxidative stress are also common symptoms. Measurement of
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the mean plasma NO levels from forty patients with bipolar disorder gave 46.58 ±
13.97 pM - and this was significantly higher than the controls of 31.81 ± 8.14 pM
from twenty-one healthy controls (Savas et al., 2002).
NO has been functionally linked to both dopaminergic and glutamatergic
systems both of which are strongly implicated in the biochemical pathology of
schizophrenia (Tsai and Coyle, 2002, Kapur and Seeman, 2002 ). At this point
and as far as schizophrenia is concerned, it still remains to be determined
whether there is a connection between the observed elevation in plasma NO
levels, and dopaminergic hyper function, or glutamatergic hypo function.
Nonetheless, high NO levels can be cytotoxic by inducing oxidative stress, and
are also know to inhibit cell respiration (mitochondria oxidative phosphorylation
and Krebs’s cycle), leading to neuronal cell death subsequent to insufficient ATP
production - and this could underlie the diffuse neuronal cell death observed in
schizophrenic brains.
In recent years, growing interest in the role of nitric oxide pathway in
idiopathic psychotic disorder such as schizophrenia has inspired lots of research
in this area. This includes the preliminary observation that Methylene blue (MB)
(which blocks NO activation of soluble guanylyl cyclase) has impressive efficacy
not only against schizophrenia, but also in the treatment of psychosis and mania
as well (Deutsh S.I., et al 1997). Consistent with this observation is the report
that NOS inhibitors such as L-NAME and 7-Nitroindazole inhibit Ketamine or
phencyclidine (PCP)-induced and MK-801-elicited schizophrenic symptoms in rat
and mice (Deutsh, 1996, Klamer et al., 2001). PCP, Ketamine and MK-801 are
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all glutamate receptor antagonists, but are highly selective for the NMDA
receptor. These drugs induce schizophrenic symptoms in humans and other
animal species by depressing the NMDA receptor, thus mimicking the
glutaminergic hypo function common in schizophrenia. Put together, these data
strongly suggest that NOS antagonists have antipsychotic actions. Hence the
development of drugs that target the glutamate system and/or, the NO/NOS
systems may represent a novel approach for the treatment of schizophrenia and
POP or Ketamine-induced psychosis.

Beneficial Activities of NO Involving the Nervous System
Memory Processing in the Hippocampus
The hippocampal Long - term potentiation (LTP) is crucial for memory
acquisition. LTP is composed of two distinct stages; a short induction stage
lasting seconds and a long expression stage lasting hours to weeks. LTP
requires about thirty minutes for consolidation i.e. become resistant to disruption
(Lynch G., 1998). This process of consolidation is associated with both the
sensitization and an increase in population of the NMDA receptor complex on the
post-synaptic neuron terminal, which is indicative of an increase of synaptic
contact area (William et al., 2003). The glutamate-dependent induction of LTP is
initiated by high frequency stimulation of the pre-synaptic axon terminal, from
which glutamate is release into the synaptic cleft (Grover and Tyler, 1994; Lynch,
1998; and Huber et al 1995). This results in increased calcium entry into the
post-synaptic neuron through the N-methyl-D- aspartate sub-type of glutamate
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receptors (NMDA). The enormous influx of calcium produces a depolarization
strong enough to relieve the voltage - dependent magnesium block of NMDA
receptor thereby increasing intracellular calcium crucial to the induction of LIP.
Subsequent changes in synaptic structures and biophysical properties trigger
production of retrograde messengers (Arachidonic acid and NO) in the postsynaptic neurons and released to induce changes in the pre-synaptic enzymatic
and transmitter release machinery i.e. more glutamate release (Bon, 1992; Bon
et al., 2000, Ko and Kelly, 1999). In the case of NO retrograde messenger,
guanylyl cyclase is activated leading to increased glutamate release from the
pre-synaptic terminal. See figure 3 below.
Additional evidence of NO involvement in synaptic plasticity and learning
are well-documented (Haley and Schuman, 1994; Richards et al., 1998; and Fin
et al., 1995). In some experiments, NOS inhibitors and / or NO scavengers such
as hemoglobin have consistently blocked LTP in the hippocampus. Promoters of
the L-arginine / NO pathway or NO donors (Fin C., et al 1995) reversed such a
blockade. Other studies have suggested that NO has a role in the acquisition of
learned behavior (Schuman and Madison, 1994; Kopf and Baratti, 1996; Richard
et al., 1998). In one such experiment, post training itraperitoneal administration of
L-NAME in male mice showed a dose-dependent decrease in the retention
latencies from a one-trial step -through inhibitory shock avoidance. In this
experimental procedure, each mouse in the treatment group was placed on a
lighted platform outside a hole leading to dark compartment. When the mouse
stepped into the dark compartment, a foot shock (0.8mM, 50 Hz for 1s) was
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delivered. After 48 hours, each mouse was again placed on the platform and the
latency to step through was recorded. Results show a dose-dependent decrease
in retention latencies upon L-NAME administration (Baratti and Kopf, 1996).
These results suggest that the L-arginine/NO pathway is involved in memory
processing and storage in the hippocampus.
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Figure 3: Illustrates glutamate released from a pre-synaptic terminal following
high frequency stimulation. It binds to post-synaptic NMDA receptors causing an
influx of calcium ions Ca2+. Alternatively, calcium influx may occur through
voltage-gated calcium channels-subsequent to depolarization triggered by the
glutamate activation of the AMPA receptors (not shown). The increased Ca2+
concentration leads to activation of NO synthase which results in a production of
NO. NO then diffuse to surrounding tissue, including the pre-synaptic release
terminal where it binds to and activates guanylyl cyclase. This sets into motion a
biochemical cascade that results in increased glutamate release from the presynaptic terminal - hence the potentiation (Adapted from the following reference:
Holscher C., 1997).
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Regulation of Sympathetic Nerves activity by nNOS Nerves
Nitric Oxide Synthase (NOS) expressing nerves have been shown to exist
in close proximity to sympathetic nerves in cerebral arteries (Toda, 1981, Toda,
and Okamura1991, and Mbaku et al 2000). These NOS nerves function to
modulate smooth muscles and adrenergic nerve activity. However, the nature of
this modulation is some what controversial in that some data suggested that NO
inhibits Norepinephrine (NE) release whereas others suggested that NO
augmented release (Thatikunta et al., 1993; Seilicovich et al., 1995, Schwarz P.,
et al 1995, Gironacci et al 1997, and Yamamoto et al 1993, Yamamoto et al
1997). Studies form our laboratory which are discussed in detail in subsequent
chapters in this thesis have shed more light on this dispute as we tested several
hypotheses in a sheep model including the following: (a) NO released by NOS
expressing neurons in cerebral arteries serves to facilitate stimulation evoked NE
release, (b) Within the cerebral arteries both the sympathetic nerves and NOS
expressing nerves are co-activated with transmural nerve stimulation. These
hypotheses were tested by direct measurement of NE and NO release in isolated
sheep middle cerebral arteries (MCA). The facial arteries (FA), which have not
been reported to contain any NOS expressing neurons, were used as a
comparison model. HPLC with redox electrochemical detection was used to
measure NE while NO was measured by chemiluminescence. Stimulation
-evoked NE release in MCA but not in the FA significantly decreased in the
presence of the NOS inhibitor N-nitro -L-arginine methyl ester (L-NAME).
Moreover, the NO donor S-nitroso-N-acetyl-DL-penicillamine (SNAP) completely

29

reversed the L-NAME effect. This suggests first, that NOS expressing nerves are
present in cerebral arteries, secondly that NO modulates NE release in MCA,
and that NO facilitates stimulation evoked NE release.
Simultaneous measurement of NE and NO were done in both arteries
following electrical stimulation. The results showed that both neuron types
(sympathetic and NOS expressing) are co-activated (Mbaku et al., 2000). The
mechanism(s) by which NO causes increase release of NE from sympathetic
nerves has been suggested (Chen and Schofield, 1995). NO gives rise to cGMP
leading to the activation of protein kinase G (PKG-1). The subsequent
phosphorylation and activation of calcium channels on post-synaptic adrenergic
neuron results in the observed increase NE release. A more recent proposal
states that the issuing PKG-1 would activate ribosyl cyclase - an enzyme that
catalyzes the conversion of NAD to cyclic ADP ribose (cADPr) which is
endogenous agonist for the ryanodine receptor.
Currently we are working at a molecular level to determine the mechanisms
by which endogenous NO enhances stimulation-evoked NE release from
adrenergic nerves in cerebral arteries. The following figure 4 illustrates a
proposed mechanism by which adrenergic nerve function is modulated by nNOS
nerves.
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Figure 4: One proposed mechanism: When the NOS cell on the left is activated
calcium influx the cell and activate Nitric Oxide synthase (NOS) which converts
L-arginine to L-citrulline with the release of NO. The newly synthesized NO
diffuse out of the cell and facilitates stimulation-evoked NE release via increase
Ca2+ influx (Chen C., et al 1995)
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Chapters 2 and 3 discuss details of our publications on modulation of
adrenergic nerves by NO nerves and the impact of development and chronic high
altitude hypoxia on this process. Chapter 4 discusses at least one possible
mechanism underlying the augmentation of NE release via NO in the
cerebrovasculature. The physiological role of the interaction between
sympathetic and nNOS nerves in cerebral arteries is yet to be defined but it might
have important effects on the control of cerebral circulation. In the next section,
we will look at the importance of cerebral circulation and a system of factors that
controls it - including the neuronal control system of which adrenergic and nNOS
nerves are important components.

Discussion
The principal objective of my research program is to investigate the
interaction between adrenergic and nNOS nerves in cerebral arteries and to
elucidate the mechanism by which NO enhances stimulation-evoked NE release
from adrenergic nerves. However, a brief physiological history of NO by way of
an overview is necessary to give us some perspective into the physiological and
pharmacological potential of this biochemical species - NO. The importance of
NO as a biological molecule can not be overemphasized - given the wide extent
of interactions it has in the physiology of a living cell. The rich nature of its
physiology with effects ranging from detrimental to beneficial, could contain
‘answers’ to questions concerning many disease conditions - including those that
might affect cerebral circulation.
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Regulation of Cerebral Perfusion
Of all the body tissues, the brain is the least tolerant of ischemia.
Interruption of cerebral blood flow for as little as 5 seconds will result in loss of
consciousness, and an ischemia lasting just a few minutes will cause irreversible
tissue damage - so that maintaining a continuous and adequate blood supply to
brain is an imperative duty. Fortunately, the regulation of cerebral circulation is
primarily under direction of the brain itself. Unlike other vascular beds, the
balance between the intrinsic and extrinsic flow-regulating mechanisms in
cerebrovasculature is in favor of the intrinsic controls and is fixed as such - or
nearly so - under normal physiological conditions. Local regulatory mechanisms
in the brain, maintain cerebral circulation at a relatively constant (optimal) level
against possible adverse extrinsic effects such as circulating humoral vasoactive
agents, and changes in the arterial blood pressure (Berne et al., 1998).

Local Factors
Generally, the total cerebral blood flow is remarkably constant over a
variety of conditions including exercise, changes in posture, mental activity and
sleep. However, regional cortical blood flow changes with regional neural activity.
Since glucose uptake and metabolic rate are directly proportional to regional
cortical neural activity, high neural activity requires not only an increase in
glucose supply to that specific cortical area (to keep up with the demand), but
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also an increase in blood flow is necessary to sweep away toxic metabolic bi
products that might rapidly accumulate.
Blood gases are also prominent regulators of cerebral perfusion especially
Carbon Dioxide (C02). Cerebral vessels are very sensitive to carbon dioxide
tension. Increases in arterial blood C02 tension (PaC02) will elicit marked
cerebral vasodilation, and the inhalation of 7% CC2 increases cerebral blood flow
twofold. Conversely, a decrease in PaC02, which can be caused by
hyperventilation, will decrease cerebral blood flow. CC2 causes these changes
by altering perivascular (and probably intracellular vascular smooth muscles) pH
which in turn alters arterial resistance (Berne et al., 1998).
Potassium ions (K+) concentration also affects cerebral blood flow.
Various stimuli such as hypoxia, electrical stimulation of the brain and seizures
elicit rapid increases in cerebral blood flow that are associated with increases in
perivascular K+ concentration (Berne et al., 1998).
Adenosine is another local factor that affects cerebral perfusion. In
response to such conditions as ischemia, hypoxemia, hypotension, hypocapnia
electrical stimulation of the brain and seizures, adenosine levels of the brain
increases. In fact any intervention that either reduces the 02 supply of the brain
or increases the 02 need of the brain results in a rapid (within 5 seconds)
formation of Adenosine in that area of cerebral tissues (Berne R.M., et al 1998).
These local factors - pH, K+ and adenosine may all act in concert to adjust the
cerebral blood flow to the metabolic activity of the brain.
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The endothelium is yet another important regulator of blood flow in
virtually all arteries of the body and cerebral arteries are no exceptions. Several
potent endothelium-derived factors are released, all of which affect the
contractility of the adjacent smooth muscles. These include the endothelium derived relaxation factor (NO), endothelium - derived hyperpolarization factors
(EDHFs), eicosatrienoic acid, prostacyclin and endothelin. See figure 5 below:
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Figure 5: Schematic demonstrating the release of putative endothelium-derived
hyperpolarizing factors (EDHFs) including NO, prostacyclin (PGE) and
eicosatrienoic acids (EETs).
• Hormones and autacoids acting at the endothelial membrane receptor (R)
or shear stress, cause G-protein-mediated hydrolysis of phosphotidyl
inositol biphosphate, yielding inositol triphosphate (IPs), which releases
calcium from intracellular stores.
• Either shear stress, membrane potential or autacoids and hormones
activate Ca2+ channels on the cell membrane. The subsequent Ca2+ influx
will trigger calcium-induced calcium release leading to a rise in [Ca2+]i.
• The resulting increase in intracellular calcium activates both NOS to
produce NO, and phospholipase A to release AA and unidentified EDHFs
• AA is converted to prostacyclin and eicosatrienoic acids, two putative
EDHFs (PGI2 and EETs).
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The endothelin is unique in that it exhibits dual functional properties,
directly responsible for arterial smooth muscle contraction and can indirectly
relax the arteries. See figure 6 below. Endothelin is synthesized in the endothelial
cells. There are two distinct endothelial receptors - ETA and ETB which are all
coupled to phospholipase C. The distribution of these receptors is such that ETB
is located on both the endothelium and smooth muscles whereas ETA is located
on smooth muscles. Activation of ETB on the endothelium resulted in relaxation
of the smooth muscles via prostacyclin / prostacyclin synthase and NO NOS
pathways (see figure 6). However, contraction results upon activation of both
ETA and ETB on smooth muscles. See illustration in Figure 6.
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Figure 6: A simplified schematic depicting the generation and action of mature
endothelin-1 in blood vessels wall: KEY: ET = endothelin; ECE = endothelin
converting enzyme; PGI2 = prostacyclin; cGMP = cyclic Guanosine
Monophosphate; cAMP = cyclic adenosine Monophosphate:
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Lastly, cerebral perfusion shows reactive hyperemia and exhibits excellent
autoregulation between the pressures of about 60 and 160 mmHg. Mean arterial
pressures below this range will result in reduced cerebral blood flow and
syncope. Whereas mean arterial pressure above 160 mmHg may lead to
increased permeability of the blood - brain barrier and cerebral edema.
Autoregulation is a phenomenon that is attributed to a myogenic mechanism
(myogenic tone) and is abolished by hypercapnia or any other potent vasodilator
(Berne R.M., et al 1998,). Under such conditions (absence of autoregulation), or
during sever high blood pressure, extrinsic regulators such as the sympathetic
activity may become very significant and can protect vital organs (Heistad D.D
and Marcus M.L., 1979).

Neural Factors
Results from pharmacological studies in isolated vascular preparations
have indicated that cerebral arteries from several species receive vasodilator and
constrictor nerves (Lee et al., 1975, 1976, 1982, 1984: Duckies et al.., 1977;
Toda 1981). TNS or field electrical stimulation of the intramural nerves has been
shown to elicit vasoconstriction, dilation or bi-model responses in isolated
cerebral arteries, depending on the region of the arteries and species of the
experimental animals examined (Lee T.J.F., et al.., 1975, 1976, 1982: Duckies et
al., 1977; Toda, 1981). The neurogenic vasodilator response of TNS, however, is
predominant in cerebral arterial segments from most species examined (Lee et
al., 1975, 1982: Winquist et al., 1982; Toda, 1981). Few cerebral arteries such as
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the basilar arteries from the rabbits (Lee et al., 1976) and sheep Duckies et al..,
1977) constricted predominantly upon TNS. The constriction
appear to be the result from excitation of the sympathetic nerves and the dilation
from that of non-adrenergic nerves (Lee, 1994).

Effects of Adrenergic Nerves
Cerebral vessels receive innervation from the cervical sympathetic nerve
fibers that originate from the superior cervical ganglion and accompany the
internal carotid and vertebral arteries into the cranial cavity. It has been shown
that these nerve fibers contain levarterenol (norepinephrine) and that they fulfill
the ultrastructural criteria for true adrenergic nerve terminals (Nelson E., and
Rennels, 1970).
Histochemical fluorescence studies have revealed considerable
differences in the density of innervation of different parts of the vascular tree
(Falck et al., 1968). The internal carotids, the posterior communicating and the
anterior cerebral arteries are densely innervated with adrenergic nerves, whereas
the middle cerebral and the basilar arteries are some what less densely
innervated. Rial arteries are moderately innervated, and only very few
adrenergic nerves supply the arterial branches radiating into the brain
parenchyma; most of these arteries however, receive no sympathetic innervation
at all (Nielsen and Owman, 1967; Falck et al., 1968). This pattern of adrenergic
innervation of cerebral vessels suggests dual control of CBF- namely the
sympathetic nervous system (controlling larger extraparenchymal vessels) and
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local autoregulatory processes (controlling small intraparenchymal vessels)
(Harper et al. 1972, and Deshmukh et al., 1972).
Apart from the possible modulation of vasodilator nerves’ function (such
as nNOS neurons), under normal physiological conditions, the direct sympathetic
control of cerebral blood vessels is weaker than in any other vascular beds so
that the contractile state of the cerebrovascular smooth muscles depends mainly
on the local metabolic factors mentioned above. Nonetheless, sympathetic
innervation may help to protect the intraparenchymal vessels during acute
hypertensive episodes and might even limit excessive intraparenchymal
vasodilation during hypercapnia (Heistad et al., 1979). Sympathetic intervention
has also been shown to protect against elevated CSF pressure (Brashear, and
Ross, Johnston, Rowan, Harper, 1971) and against the disruption of the Blood
Brain Barrier during severe hypertension (Heistad and Marcus 1979).

Effects of NOS-expressing Neurons
The nature of the transmitter substance for cerebral vasodilation was first
suggested based on in vivo physiological studies to be Acetyl choline (Chorobski,
and Penfield, 1932). However, in isolated cerebral arteries of cat, Lee et al.,
1982, demonstrated that Ach was unlikely to be the transmitter. Since then,
several potential substances such as vasoactive intestinal polypeptide (VIP) and
calcitonin gene-related peptide (CGRP) have been suggested to be transmitters
for cerebral vasodilation (Lee et al., 1984; Saito et al., 1988). Nitric Oxide (NO)
however, has recently been shown to mediate a major component of the TNS-
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elicited vasodilation in cerebral arteries of the pig, cat and other species (Lee,
1994). Results have also shown that nicotine-induced vasodilation in isolated
cerebral arteries (denuded of endothelium) from several species including human
is mainly due to NO (Toda, 1993). Additional evidence supporting the hypothesis
that NO is the neurotransmitter involved in cerebral vasodilator response include
the following: (1) the ability of indigenous NO to relax vascular smooth muscles
(Barroso et al., 1996) and (2) a possible reciprocal interaction between nitric
oxide synthase-expressing neurons and sympathetic nerves in the cerebral
arteries (Zhang et al., 1998, Min-Liang and Lee, 2001; Lee, Zhang; and
Sarwinski, 2000).
Morphological studies have demonstrated that the close apposition
between the adrenergic nerves and nitric oxide synthase-immunoreactive nerve
terminals, are frequently found in large cerebral arteries at the base of the brain
in several species (Barroso et al., 1996, Iwayama et al., 1970, Lee, 1981). The
axo-axonal distance between these different types of nerve terminals is
substantially closer than the synaptic distance between the adventitial nerve
terminals and the outermost layer of the smooth muscle in the media (Iwayama
et al., 1970; and Lee, 1981; Lee and Satio, 1984). This morphological feature
suggests that a functional axo-axonal interaction (which may be reciprocal in
nature) between these nerve terminals is more likely to occur than that between
the nerve and muscle. Thus transmitters released from one nerve terminal may
modulate the release of transmitters from the neighboring nerve terminals and
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therefore the neurogenic vasomotor responses (Lee 1981; and Edvinsson et al

1977).
In the superior cervical ganglion (SCG), the relay center for sympathetic
innervation from the CNS to cerebral arteries, nitric oxide synthase-expressing
neurons have been shown to exist in close approximation with sympathetic
nerves (Dunet al., 1995). Furthermore, nitric oxide synthase immunoreactivity
has been localized to sympathetic preganglionic neurons in the intermediolateral
cell column and cyclic GMP (cGMP) immunoreactivity to nerve fibers projecting
into the intermediolateral cell column of rat (Wu et al., 1997). These observations
indicate that nitric oxide may facilitate the release of excitatory transmitters,
possibly through a presynaptic cGMP-dependent mechanism. Despite numerous
reports on the possibility of a functional interaction between adrenergic and nitric
oxide synthase immunoreactive neurons in cerebral arteries and related ganglia,
the exact nature and / or the mechanism involved in such interaction, is not yet a
settled issue. In order to shed light on this rather shady area, my research has
focused on: (a) examining the possible modulation of adrenergic nerve function
by nitric oxide synthase-expressing neurons in fetal and adult sheep cerebral
arteries, and also to examine the adaptive (changes if any) in such modulation in
response to stress such as chronic high altitude hypoxemia (b) attempt to derive
an explanation for the adaptive changes observed (c) determining the
mechanism(s) at a molecular level by which such a modulation occurs.
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Chapter 2
Nitric-Oxide Synthase-Containing Nerves Facilitate Adrenergic
Transmitter Release in Sheep Middle Cerebral Arteries.

Abstract
Cerebral blood vessels contain both sympathetic and nitric oxide (NO)
synthase (NOS)-containing nerves. NO has been proposed to modulate smooth
muscle function and adrenergic nerve activity and the nature of this modulation is
controversial: some data show NO inhibits norepinephrine (NE) release, whereas
others suggest that NO augments release. To test the hypothesis that in cerebral
arteries NO released by NOS-containing nerves augments stimulation-evoked
NE release, we used direct measurement to NO and NE release in isolated
sheep middle cerebral arteries. The facial arteries, which have not been reported
to be innervated with NOS-containing nerves, were used as a comparison model.
HPLC and redox electrochemical detection was used to measure NE and NO
was measured by chemiluminescence. Stimulation -evoked NE release from the
middle cerebral artery significantly declined in the presence of the NOS inhibitor
AT-nitro-L-arginine methyl ester (L-NAME). The effect of L-NAME was reversed
by the addition of the NO donor S-nitroso-N-acetyl-DL-penicillamine (SNAP). In
contrast, in facial arteries, L-NAME had no effect on stimulation-evoked NE
release, whereas S-nitroso-N-acetyl-DL-penicillamine (SNAP) still significantly
elevated NE release in both the middle cerebral and facial arteries. However,
when NO was measured in the same samples, stimulation-evoked release of NO
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was significantly increased compared with basal release only in middle cerebral
arteries. These data support the concept that cerebral arteries in the sheep
contain both adrenergic and NOS-containing nerves. Furthermore, this study
provides succinct evidence that NO release from NOS nerves augments
stimulation-evoked NE release.

Introduction
Cerebral arteries contain both sympathetic and nitric oxide synthasecontaining nerves. However, the relative importance of these nerves in regulating
cerebral blood flow remained controversial (Bill and Linder, 1976; Bevan, 1981;
Busija and Heistad, 1984; Buchholz et al 1999). Although adrenergic nerve
stimulation may not play a major role in the control of cerebral blood flow under
normal physiologic conditions, when arterial blood pressure is elevated,
sympathetic nerve causes a marked blunting of the increase in cerebral blood
flow (Bill and Linder, 1976). Thus sympathetic nerve activity may serve to protect
individual organisms against environmental stress (Busija, 1984; Faucher et al
1991).
Since the discovery of nitric oxide gas (NO) as the endogenous
endothelium derived relaxation factor (EDRF) in mammalian cells, it seems to be
omnipresent in mammalian biology (Nathan, 1992; Michel and Feron, 1997).
Nerves containing NO synthase (NOS) have been shown to innervate canine and
porcine cerebral arteries, suggesting a role for NO beyond that of relaxation of
vascular smooth muscles (Lee and Sarwinski, 1991; Toda and Okamura, 1991).
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For example, transmural nerve stimulation has been shown to promote the
release of NO from canine middle cerebral arteries, an effect abolished by
tetrodotoxin (Toda and Okamura, 1990). Similar results have been demonstrated
in endothelium-denuded canine cerebral artery strips that relaxed in response to
nerve stimulation. This effect was inhibited by an NOS inhibitor and abolished
with tetrodotoxin, suggesting that NO from a neuronal source (Toda and
Okamura, 1991) mediates such relaxation.
During the late 1980s several reports have been have suggested that NO
may modulate adrenergic nerve activity. However, the results are controversial.
For instance in rabbit carotid arteries, it was reported that stimulation-evoke NE
release is inhibited by endothelium-derived NO (Cohen and Weisbrod, 1988;
Tesfamariam et al, 1989). In rat medial basal hypothalamus, the NO donor
sodium nitroprusside inhibited, whereas an NOS inhibitor enhanced K+ - evoked
norepinephrine (NE) release (Seilicovich et al, 1995). NE release from heart
sympathetic nerves was also shown to be enhanced by inhibition of NOS
(Schwarz et al, 1995). These studies all suggest that NO inhibits NE release from
adrenergic nerves.
In contrast, there also are a number of studies demonstrating the
opposite. That is NO enhances NE release from adrenergic nerves. Inhibition of
NOS decreased stimulation-evoked NE release in rat atria and mesenteric
arteries, and these effects were reversed in by L-arginine (Yamamoto et al, 1993,
1997; Gironacci et al 1997). In the anesthetized opossum, NE release induced by
hypo gastric nerve stimulation was also attenuated by NOS inhibition, and this
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effect was reversed by L-arginine (Prakash et al, 1993). In rat cerebral cortex, Nmethyl-D-aspartate-induced NE release was inhibited by an NOS antagonist
(Montague et al 1994). In similar studies the direct application of NO enhanced
K+ - evoked NE release from rat cerebral cortex synaptosomes and hippocampal
slices (Stout and Woodward, 1994; Martire et al, 1998). Thus, it is still not clear
how to explain these conflicting results.
Given that the cerebral vasculature contains both adrenergic and NOproducing nerves and that there are no studies on possible interactions between
these nerve types in this vascular bed, a study of this nature was initiated.
Stimulation-evoked release of both NE and NO was measured in the middle
cerebral arteries from adult female sheep. Using the facial artery as a peripheral
arterial comparison, we tested the following two hypotheses; 1) in the cerebral
vasculature, stimulation that simultaneously activates both NOS-containing
nerves and adrenergic nerves will result in increased overflow of both
transmitters, NO and NE. Nerve stimulation will not evoke NO release in the
facial arteries; and 2) release of NO from NOS-containing nerves will augment
stimulation-evoked NE release from adrenergic nerves in cerebral arteries.

Materials and Methods
Adult non pregnant ewes obtained from a single supplier (Nebeker Ranch,
Lancaster, CA) and were sedated with an i.v. injection of sodium pentothal
(100mg/Kg). The animals are then sacrificed by bleeding from the jugular
arteries. The facial arteries and the brain were extracted and immediately placed
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in separate beakers containing ice-cold Krebs’ solution with subsequent
dissection of the middle cerebral arteries. The Krebs’ solution contained 118 mM
NaCI, 4.8 mM KCI, 1.6 mM CaCI2) 1.2 mM KH2PO4, 25 mM NaHC03, 1.2 mM
MgSCU, 0.3mM ascorbic acid, and 11.5 mM glucose.

Tissue Preparation
Segments of the middle cerebral and facial arteries (3-4 cm) were
cannulated at both ends with polyethylene tubing and mounted on the low
volume perfusion system as previously described (Buchholz and Duckies, 1992).
The middle cerebral artery segment used was the main branch from the circle of
Willis. Middle cerebral artery diameters vary from 0.8 to 1.1mm and facial
diameter range from 1.4mm. Arteries were perfused at the rate of 1 .Oml/min,
creating a perfusion pressure of about 55 to 65mmHg in both artery types. The
entire perfusion system were immersed in a circulation hot water bath and kept at
37°C. Tissues were perfused throughout the experiment with aerated (95% O2,
5% C02) Krebs’ solution containing 10'5 M erchloricosterone and 10‘5 M cocaine
to inhibit extra - neuronal and neuronal NE uptake respectively. In all
experiments, a Grass S-48 model stimulator (Grass Instruments, Quincy, MA)
delivered electrical field stimulation to perivascular nerves through a pair of
platinum electrodes. The parameters for stimulation were 8Hz, 60 V, 1ms
duration, and 480 pulses (1-min stimulation).
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Effect of N -Nitro-L-arginine Methyl Ester (L-NAME) and S-Nitroso-N-acetylDL - penicillamine (SNAP) on Stimulation-Evoked NE Release
In Figure 1, actual data from one pair of middle cerebral and facial arteries
illustrate the protocol used to test the effects on NE release of NOS inhibition
with L-NAME. Perivascular nerves in the control arteries (Fig. 1, A and C were
activated three consecutive times (S1-S3) for 1 min with a 45-min equilibration
between each stimulation. Perivascular nerves in treatment tissue (Fig. 1 B) and
D were activated one time (S1) followed by a 45 - min equilibration period. After
S1, tissues were exposed for 20 min to 10pM L-NAME and activated for 1 min
followed by an additional 45 - min equilibration period. Finally, tissues were
exposed for 15 - min to 10pM L-NAME and 25 pM SNAP and again the nerves
were activated for 1 - min. Basal NE release was monitored by taking a 5 - ml
sample before each stimulation in both time control and treatment arteries.

Simultaneous Assay of NE and NO Release
Nerves were activated for 1 - min two consecutive times with a 45 - min
period separating S1 and S2. Perfusate was collected during the stimulation
period until a total of 5 ml was collected. A 900 pi aliquot was obtained and
immediately snap frozen in liquid nitrogen and stored at -80°C until NO analysis
was carried out. The remaining 4.1-ml sample was used for the measurement of
NE. Basal release was monitored by collecting a 5 - ml sample prior to individual
stimulation.
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Measurement of NE
The NE in the perfusate was extracted with alumina at a pH of 8.6 and
quantified with dihydroxybenzylamine (DHBA) as an internal standard (400 pg)
using a previously described protocol (Buchholz and Duckies, 1992). A 100 - pi
sample of extracted amine was injected into an ESA Coulochem II high
performance liquid chromatography (ESA, Bedford, MA) and separated on an
ESA reverse phase C18 column with ESA MD-TM aqueous mobile phase. The
mobile phase contained 75 mM Na2H2P04, 0.5 M SDS, 0.025 mM EDTA, 20%
acetonitrile and 5% methanol. The following formula was used to calculate the
amount of NE in the injected sample. Recovery varied from 85 to 99%.
NE = (NE peak Ht sample)/ (NE peak Ht standard) x 100pg DHBA x (DHBA peak
Ht standard)/(DHBA peak Ht sample)

1, where Ht is height. To quantify tissue

NE content, arteries were taken at the end of each experiment and homogenized
in 3 ml of 0.1 N erchloric acid, followed by centrifugation. A 300 pi aliquot of the
supernatant was taken and NE was extracted in a similar manner as the
perfusate. NE content was used to calculate fractional NE release.
Fractional NE release = NE release (pg) / NE tissue content (pg) x number of
stimulation pulses (2)

Measurement of NO
Frozen aliquots of perfusates were thawed, and NO was measured as
previously described (Xiao et al, 1999). Briefly, NO was measured by injection of
a 100 pi aliquot of the perfusate into a Siever 270B NO analyzer (Sievers
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Instruments, Boulder, CO) in which stable nitrate and nitrite are reduced to NO
gas. NO is measured by a reaction with ozone, yielding light detected by a
photomultiplier tube. Calibration curves were run during each analysis, and
individual standard curves (0-200 pmol) were used to convert subsequent NO
signals into pmol of Nox. See Figure 1.

Statistical Analysis: Effects of L-NAME and SNAP treatment on stimulation evoked NE release relative to control arteries were analyzed by paired Student’s
t- test. Comparison of stimulation - evoked NO release to basal was also
determined by paired t-test.

Drugs used: Cocaine hydrochloride, deoxycorticosterone, L-NAME, and SNAP
were all obtained from Sigma Chemical Co. (St. Louis, MO).
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Figure 1: Diagram showing the basic functioning of a Siever 270B NO analyzer.
Oxygen comes in through the air inlet into the ozone generator, which
synthesizes and pumps the ozone into the reaction chamber containing a mixture
of Vanadium III chloride and concentrated HCI. Helium from an external tank also
feeds in the reaction chamber which is connected to a photomultiplier tube
(PMT). A circulating hot water bath (not shown) maintains the reaction chamber
at the optimal temperature of 90°C throughout the entire experiment.
Nitrates and nitrites in the samples are reduced to NO by hot V3+ / H+
and the NO is converted to N02 by the 03. The gaseous N02 diffuses into the
PMT where in is ionized. A photon counter connected in series with the PMT
converts the electron beam to a signal that can be saved and / or displayed on
the monitor.
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Results
NE and NO Release
Activation of perivascular nerves significantly increased fractional NE
release in both the middle cerebral and facial arteries (Fig 2, A and C). In middle
cerebral artery stimulation -evoked release of NO was significantly increased
compared to the basal (Fig. 2B). In contrast, in facial arteries, stimulation-evoke
release of NO and basal release were not significantly different (Fig 2D).

Effects of NO Synthase Inhibition and NO Donor SNAP
Effects of the NOS inhibitor L-NAME and the NO donor SNAP on
stimulation - evoked NE release are shown in fig. 3. Stimulation - evoked NE
release from adrenergic nerves in the middle cerebral and facial arteries was
consistent over the experimental time course, (time controls fig. 3, A and C).
In contrast, L-NAME had no significant effect on stimulation evoked NE
release from adrenergic nerves in the facial arteries (Fig. 3D). However, the
addition of SNAP significantly elevated stimulation-evoked NE release (Fig. 3D).
Basal NE release was consistent during the experimental time course. The
addition of L-NAME or SNAP did not significantly alter basal NE release in either
middle cerebral or facial arteries (Table 1)
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Figure 2: Representative data to illustrate experimental protocol for
measurement of stimulation-evoked NE release in middle cerebral and facial
arteries. Tissues were exposed throughout the experiment to
Deoxycorticosterone and cocaine (10-5 M). Perivascular nerves were activated
three consecutive times [stimulation (S1-S3)], each for 1 min, with a 45 min
equilibration separating each stimulation train. In every experiment, one artery
served as a time control (A and C). In treated tissues (B and D) after S1, tissue
were exposed to lOpM L-NAME and 25pM SNAP for 15 min and activated again
for 1min.
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Figure 3: Measurement of stimulation-evoked NE and NO release from
perivascular nerves middle cerebral and facial arteries. Tissues were exposed
throughout to deoxycorticosterone and cocaine (10 5 M). Perivascular nerves
were activated two consecutive times [stimulation (S1-S2)], each for 1 min with a
45 min equilibration between each stimulation train. Both stimulation evoked NE
and NO release were measured in each sample. Columns represent the mean ±
S.E., *, significantly different from basal release (P< 0.05; n = 7 middle cerebral
and facial arteries).
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Figure 4: Effect of L-NAME and the NO donor SNAP on stimulation-evoked NE
release in middle cerebral and facial arteries. In each experiment, one tissue
served as a time control (A and C) to establish the consistency of NE release.
Tissues were exposed throughout the experiment to deoxycorticosterone and
cocaine (10~5 M). Treatment with L-NAME and SNAP was carried out as
described in the text and illustrated in fig 3 (1). Columns represent the mean ±
S.E., **, significantly different from two other treatments (i.e., S1 and S3 or S1
and S2) by paired t test (P< 0.05; n = 5 - 10 arteries)
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S3

Table 1
Effect treatment on basal NE release from middle cerebral and facial arteries is
shown in this table. Values represent the mean ± S.E., (n = 5 - 10 arteries). All
tissues were treated with deoxycorticosterone (10-5 M) and cocaine (10-5 M).

Basal NE release
Middle Cerebral Artery

Time Control

Facial Artery

Pg /pg content

Pg/pg content

Basal 1

0.0020 ± 0.00024

0.0020 ± 0.00051

Basal 2

0.0015 ±0.00026

0.0016 ±0.00032

Basal 3

0.0014 ±0.00029

0.0015 ±0.00027

Basal 1

0.0020 ± 0.00055

0.0014 ±0.00015

Basal 2

0.0021 ± 0.00037

0.0015 ±0.00012

Basal 3

0.0020 ± 0.00066

0.0013 ±0.00011

Treatment
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Discussion
The discovery that the gas NO released from the endothelium modulates
vascular tone ranks as one of the most significant recent findings in Physiology
and Pharmacology (Michel and Feron, 1997). The sheer number of publications
on the subject of NO suggests that NO plays almost a universal role in the
modulation of cellular function. However, the regulation of autonomic nerve
activity by NO is a relatively novel and understudied topic.
The most important and interesting findings in this study is that
stimulation-evoked NE release from sympathetic nerve terminals in cerebral
arteries is augmented by NO released from NOS-containing nerves. Blockade of
NOS with L-NAME significantly inhibited stimulation-evoked NE release in middle
cerebral arteries. In addition, the effect of L-NAME was fully reversed by
application of the NO donor SNAP. In contrast, L-NAME had no effect on
stimulation-evoked NE release in the facial arteries; however, SNAP significantly
elevated stimulation-evoked NE release. These data suggest that NO facilitates
adrenergic nerve transmission. Further more, although facial arteries are not
known to be innervated by NOS-containing nerves, and L-NAME had no effect,
the addition of an NO donor still enhanced NE release in this tissue, suggesting
that the adrenergic nerves still posses the mechanism for response to NO. This
study confirms our previous suggestion that NOS nerves serve to augment
adrenergic nerve activity in the sheep cerebral vasculature (Buchholz et al.,
1999).
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The present report clearly shows that NO augments NE release in
cerebral arteries and this result is supported by a number of studies in other
tissues. In the rat atria, mesentery, and central nervous system, NO appears to
augment NE release from adrenergic nerves (Yamamoto et al., 1993, 1997;
Montague et al 1994; Stout and Woodward, 1994; Gironacci et al., 1997; Martire
et al., 1998). However, our results and those of others showing that NO
augments NE release stand in distinct contrast to several other reports. For
example, in rabbit carotid arteries and rat hypothalamus and heart, NO has been
suggested to inhibit NE release (Cohen and Weisbrod, 1988; Tesfamariam et al.,
1989; Schwarz et al., 1995; Seilicovich et al., 1995).
There could be many possible reasons for these different results; we
suggest at least three. The first possibility rests on the knowledge that arterial
endothelium releases numerous substances in addition to NO, including
prostaglandins, endothelin, and endothelium-derived hyperpolarizing factor
(Hasunuma et al., 1990; Nakashima and Vanhoutte, 1993; Koller and Huang
1995; Koller et al., 1998). Given the number of different substances released
from the endothelium, there is a possibility that any one of these endothelial
factors may have prejunctional effects. Thus, reports cited earlier demonstrating
that endothelial removal modulates NE release may not necessary be related to
prejunctional effects of NO per se. In addition, it is possible that contrasting
results may reflect that NO exerts a different effect in similar models in different
species, suggesting that indeed NO may have broader regulatory functions.
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Another possibility for these contrasting results may be more technical in
nature. In all of the reports that have shown that NO may inhibits NE release, NE
was quantified by HPLC with electrochemical detection using a single oxidizing
electrode. However, the direct application of increasing concentrations of NO
itself or the NO donor sodium nitroprusside has been shown to decrease the
amount of NE quantified by a single oxidizing electrochemical electrode
(McArthur et al., 1995). Furthermore, using spectroscopic methods, it was shown
that NO can oxidize NE to its quinone product. NE in this oxidized state (quinone
state) cannot be detected by a single oxidizing electrode, and this could lead to
data suggesting that NO actually decreases NE release. In addition, the
biological significance of the oxidation of NE by NO and the consequence for
vascular function must be explored.
In contrast, in the current report and two others suggesting that NO
augments NE release, HPLC was linked to an ESA “redox” detector (Yamamoto
et al., 1993, 1997). This detector type uses two high surface area electrodes in
series. The first electrode (reduction electrode) reduces any NE that has been
oxidized, whereas the second electrode oxidizes NE, producing the recorded
signal. Thus, using this redox method of NE quantification, oxidation of NE by NO
would be of no consequence, and this method would detect all NE released. In
agreement with studies using HPLC with a redox detector, studies using 3Hlabeled NE also showed that NO augments NE release (Montague et al., 1994;
Stout and Woodward, 1994; Gironacci et al., 1997; Martire et al., 1998). 3H-
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labled NE even if oxidized, would still be measured because reduced and
oxidized forms of NE would all be quantified as total tritium released.
A mechanism for the enhancement of NE release by NO has been
proposed. In superior cervical cells, NO donors such as SNAP have been shown
to increase Ca2+ current amplitude. Furthermore, the application of cGMP also
increased the amplitude of Ca2+ currents, thus mimicking the effects of NO
donors on Ca2+ channels to depolarization. Facilitation of Ca2+ current is at least
on rational explanation for the positive modulation of NE release by NO found in
our study.
The coexistence of NOS-containing nerves and adrenergic nerves in
cerebral blood vessels has been demonstrated. In canine cerebral arteries, the
activation of vasodilator nerves releases NO; this is inhibited by L-NAME and
abolished by tetrodotoxin. These data suggest that the origin of the NO is
neuronal (Toda and Okamura, 1990, 1991). Indeed, when we measured both NE
and NO releases in the same sample, activation of perivascular nerves
significantly increased both NE and NO releases in the middle cerebral arteries.
In contrast, activation of perivascular nerves in facial arteries only elevated NE
release, with no effect on NO release. These data provide another piece of
evidence that the cerebral vasculature contains both adrenergic and NOScontaining nerves.
There is evidence that alterations in flow or shear stress induce the
release of NO from the endothelium (Koller and Fluang, 1995; Corson et al.,
1996; Koller et al., 1998). The present finding of the ample release of NO in the
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absence of electrical stimulation (basal NO release; Fig 2, B and D) suggests
that NO is released from the endothelium in isolated, perfused middle cerebral
and facial arteries. Furthermore, at identical flow rates and similar perfusion
pressures (1.0 ml/min; 55-65 mmHg), basal NO release was similar in the two
arteries. However, a significant elevation in NO release when perivascular nerves
are activated was seen only in cerebral arteries. This result further suggests a
neuronal source of stimulation-evoked NO release in cerebral arteries.
In conclusion, we have shown that adrenergic nerves in blood vessels are
regulated by NO and that NO augment NE release in adrenergic nerves in both
cerebral and facial arteries. Furthermore, our data suggest that the cerebral
arteries are unique in containing both adrenergic and a source of NO that appear
to be derived from NOS-containing nerves. This report underscores the idea that
NO has diverse regulatory functions, including the regulation of vascular
adrenergic nerves. This study also implies that there is another layer of
regulation of adrenergic nerves in addition to other well-studied neuromodulatory
mechanisms. For references refer to JEP 293: 397-402, 2000 online
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Chapter 3
Chronic hypoxia alters the function of NOS nerve in cerebral arteries of near-term
fetal and adult sheep.

Abstract
In addition to adrenergic innervation, cerebral arteries also contain
neuronal nitric oxide synthase (nNOS)-expressing nerves that augment
adrenergic nerves function. We examined the impact of development and chronic
high altitude hypoxia (3820m) on nNOS nerve function in near term fetal and
adult sheep middle cerebral arteries (MCA). Electrical stimulation-evoked release
of norepinephrine (NE) was measured with HPLC and electrochemical detection,
while nitric oxide (NO) release was measured by chemiluminescence. An
inhibitor of NOS, N^-nitro-L-arginine methyl ester (L-NAME) significantly inhibited
stimulation-evoked NE release in MCA from normoxic fetal and adult sheep with
no effect in MCA from hypoxic animals. Addition of the NO donor S-nitroso-Nacetylpenicillamine (SNAP) fully reversed the effect of L-NAME in MCA from
normoxic animals with no effect in MCA from hypoxic animals. Electrical
stimulation caused a significant increase in NO release in MCA from normoxic
animals, and effect that was blocked by the neurotoxin tetrodotoxin, while there
was no increase in NO release in MCA from hypoxic animals. Relative
abundance of nNOS as measured by western blot analysis was similar in
normoxic fetal and adult MCA. However, following hypoxic acclimatization nNOS
levels dramatically declined in both fetal and adult MCA. These data suggest that
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the function of nNOS nerves declines during chronic high altitude hypoxia - a
functional change that may be related to a decline in nNOS protein levels.

Introduction
Although the cerebrovascular network of vessels is well innervated by
sympathetic nerves their contribution to the control of cerebral blood flow (CBF)
under normal physiological conditions is unclear (Bill and Linder, 1976; Busja and
Heisted, 1984; Buchholz et. al., 1999). Under normal variations in blood
pressure autoregulatory responses adjust luminal diameter in order to keep blood
flow constant (Busija and Heisted, 1984; Geary et. al., 1998). However, when
arterial pressure is elevated (150-180 mm Hg) sympathetic nerve activation will
blunt increases in cerebral blood flow and possibly prevent disruption of the
blood brain barrier (Heisted and Marcus, 1979; Busja et. al. 1980). Thus,
sympathetic nerves have been suggested to protect an organism from various
stresses such as severe hypotension, hypertension or hypercapnia (Busja and
Heisted, 1984; Faucheret. al., 1991)
In addition to sympathetic nerves there is a convergence of data
suggesting that the cerebrovasculature contain neuronal nitric oxide synthase
(nNOS) nerves that release nitric oxide (NO) in different mammalian models
(Duckies, 1979; Lee and Sarwinski, 1991; Toda et. al., 1991). More recent
studies using immunohistochemical techniques have illuminated the structural
proximity of sympathetic and nNOS neurons. Indeed in the porcine
cerebrovasculature and rat superior cervical ganglion nNOS neurons and
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sympathetic neurons are in very close proximity suggesting that they may have a
functional interaction (Dun et al 1995; Wu et. al., 1997; Zhang et. al., 1998; Lee
et. al.,2000; Si and Lee, 2001). Functional studies in dog middle cerebral artery
(MCA) strips denuded of the endothelium have shown that both transmural nerve
stimulation (INS) and nicotine induces a relaxation that is blocked by NOS
antagonists and the neuronal poison tetrodotoxin (Toda and Okumura, 1990b;
Toda and Okamura, 1991). These data suggest that NO is liberated during
nerve stimulation in cerebral arteries and further suggest that MCA contains a
neuronal source of NO. In perfused sheep MCA our studies have shown that
TNS increases the overflow of both norepinephrine (NE) and NO while in the
facial artery TNS increase overflow of NE but not NO (Mbaku et. al., 2000). All of
these studies strongly suggest that during nerve activation in the
cerebrovasculature NE and NO are released from neuronal sources.
Recently studies have demonstrated a functional interaction between
sympathetic and nNOS nerves in the cerebrovasculature. Nicotine-induced
relaxation via nNOS nerves in cerebral artery strips requires functional
sympathetic neurons (Zhang et. al. 1998; Si and Lee, 2001). In porcine basilar
arteries activation of sympathetic ganglia and release of norepinephrine
subsequently activates adjacent nNOS nerves and sympathetic denervation or
b2-adrenoceptor antagonists block this effect. (Zhang and Lee 1998; Lee et. al.,
2000). Furthermore, the ay-nicotinic receptor on sympathetic ganglia appears to
mediate nicotine induced neurogenic vasodilation (Si and Lee, 2001).
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The release of NO from nNOS nerves has been shown to augment
stimulation-evoked NE release. In rat cerebral cortex N-methyl-D-aspartate
induced and K+-evoked NE release from hippocampal slices is blocked by NOS
antagonists (Montague et. al., 1994; Martire et. al., 1998). Consistent with these
studies, in sheep MCA nitric oxide synathase antagonists have been shown to
inhibit norepinephrine release (Buchholz et. al, 1999; Mbaku et. al., 2000).
Overall the studies cited above demonstrate a morphology consistent with an
axo-axonal interaction between sympathetic and nNOS neurons and further
suggest that there is a direct functional interaction between these neurons. In
addition, these studies may provide some insights into the importance of NO as
neurotransmitter and as a possible modulator of cerebral perfusion and
sympathetic nerves.

Despite numerous evidences that support the interaction between nNOS
and sympathetic nerves, no studies have been done to examine the impact of
stress factors such as chronic high altitude hypoxemia on the functional relation
between endogenous nNOS and sympathetic nerves in cerebral vessels. In the
present study we measured stimulation-evoked norepinephrine and NO release
in the MCA from normoxic and hypoxic near term fetal and adult sheep. The
facial artery (FA) was used as a comparison model since they have not been
reported to contain any nNOS nerves. In addition, we quantified the relative
abundance of nNOS in cerebrovascular blood vessels using western blot
analysis and a recombinant "bNOS" standard. We addressed two hypotheses.
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(1) nNOS nerves in the cerebrovasculature modulate stimulation-evoked
norepinephrine release in the cerebrovasculature and that the function of nNOS
nerves are altered during high-altitude acclimatization in the fetus as well as the
adult sheep. (2) An alteration in the function of nNOS during high-altitude
acclimatization is related in part to altered nNOS levels in cerebral arteries.

Materials and Methods
Twenty-six pregnant and twenty-six non-pregnant ewes of mixed breed
were obtained from one supplier (Nebeker Ranch, Lancaster, CA). These
animals were randomly separated into two groups, control normoxic (13 pregnant
and 13 non-pregnant) and long-term hypoxic (13 pregnant and 13 non-pregnant).
Animals in the hypoxic group were transferred to the White Mountain Research
Station (Bishop, CA, attitude of 3280 m). Ewes in the control group remained at
Nebeker ranch (718 m). At 138-142 days gestation, pregnant and non-pregnant
normoxic and hypoxic animals were transported to Loma Linda University
Department of Perinatal Biology where they underwent immediate study. In the
case of hypoxic ewes awaiting study a non-conclusive tracheal catheter was
surgically implanted (Gleed et. al., 1986) to allow the administration of N2 gas,
maintaining the arterial partial pressure of oxygen (P02) at * 60 Torn Arterial
P02 in the adults was measured 0.5 ml blood samples (ABL300; Radiometer,
Copenhagen, Denmark). The mean PO2 for normoxic was adults was 100 ± 2
torr and for hypoxic adults, 60 ± 3 torr. Mean PO2 values in for normoxic fetuses
wash 23 ± 1 torr and for hypoxic fetuses 19 ± 0.7 torr. On the day of the
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experiment, ewes were euthanized by an i.v injection of pentobarbital sodium
(100 mg/kg), and near term fetuses delivered by cesarean section. Fetal weights
were not significantly affected by hypoxia. The fetal weights were 4409 ± 263 g
for hypoxic and 4263 ± 138 g for normoxic animals. Facial arteries and brain
were removed from adults and fetuses and immediately placed in separate
beakers containing ice-cold Krebs solution. Dissection of middle cerebral
arteries followed. The Kreb's solution contained (in mM): 118 NaCI, 4.8 KCI. 1.6
CaCI2, 1.2 KH2PO4, 25 NaHC03, 1.2 MgS04 0.3 ascorbic acid and 11.5 glucose.

Tissue preparation: Three to four cm segments of middle cerebral arteries
(MCA) and comparison model the facial artery (FA) were cannulated at both
ends and mounted on a low volume perfusion system as previously described
(Buchholz and Duckies, 1992). The middle cerebral artery segment used was
the main branch from the circle of Willis. The diameters of middle cerebral and
facial arteries ranged from 0.8 to 1 mm and 1 to 1.4 mm respectively. Arteries
were perfused at a rate of 1-ml per minute with aerated (95% 02, 5% C02) Krebs
creating a perfusion pressure of approximately 60-70 mm Hg in either artery
type. The entire assembly was immersed in a circulating water bath kept at 37°
C. In all experiments, a Grass S-48 model stimulator (Grass Instruments,
Quincy, MA) delivered electrical field stimulation to perivascular nerves through a
pair of platinum electrodes. The stimulation parameters were 8 Hz, 60 V, 1-ms
duration, and 480 pulses (1-min stimulation).
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Simultaneous Assay of NE and NO Release: Nerves were once for 1 min
followed by a 45 min equilibration. Tissues were then exposed for 30 min to the
neuronal toxin tetrodotoxin (1 pM, TTX), to test the neurogenic orgin of
stimulation-evoked release of NE and NO, and nerves were activated again for 1
min. The perfusates were collected during the stimulation until 5 ml was
collected. A 900-pl aliquot was immediately snap frozen in liquid nitrogen and
stored at -80° C until NO analysis was performed. The remaining 4.1-ml of the
sample was assayed for NE. Basal release was monitored by collecting a 5-ml
sample before activation of perivascular nerves.

Effect of Nw- Nitro-L-arginine Methy Ester (L-NAME) and S-Nitroso-N-acetyl
-DL-Penicallamine (SNAP) on Stimulation-Evoked NE release: This protocol
was designed to test the effects of NOS inhibition on NE release with L-NAME.
Perivascular nerves in the control arteries were activated three consecutive times
(Si -S3) for 1-min with a 45-min equilibration between each stimulation. In the
treatment tissues perivascular nerves were activated once for 1-min (Si) followed
by a 45-min equilibration. Following Si, tissues were equilibrated in buffer
containing 10 pM L-NAME for 20 min and activated for 1 min (S2) followed by
another 45-min equilibration period. Finally, tissues were equilibrated in buffer
containing 10 pM L-NAME and the NO donor SNAP, and again the nerves were
activated for 1-min (S3). Basal NE release was monitored by taking a 5-ml
sample prior to each stimulation in both the time control and treatment arteries.

77

Measurement of NE: In each sample of perfusate the NE was extracted with
alumina at pH 8.6 and quantified with dihydroxybenzylamine (DHBA, 400 pg)
using a protocol described previously (Buchholz and Duckies, 1992). A 100-pl
sample of the extracted amines were injected into an ESA Coulochem II high
performance liquid chromatograph (ESA, Bedford, MA) and separated on an
ESA reversed phase C18 column. The ESA MD-TM eluting mobile phase
contained 75 mM Na2H2P04, 0.5 M SDS, 0.025 EDTA, 20% acetonitrile and 5%
methanol. The amount of NE in the injected samples was calculated with the
following equation and recovery varied from 85 to 98%.
NE(pg) = NE Peak Ht sample

x 100 pg DHBA x DHBA peak Ht standard

NE peak Ht standard

(1)

DHBA peak Ht sample

where Ht is height. Quantification of tissue NE content was accomplished by
homogenizing arteries in 3-ml of 0.1 N perchloric acid, followed by centrifugation.
A 300-pl aliquot of the supernatant was taken and NE extracted in a similar
manner as the perfusate. NE content was used to calculate fractional NE
release.
Fractional NE release
Total NE release (pg)
NE tissue content (pg) x number of stimulation pulses
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(2)

Measurement of NO: NO was measured with the 280 Seiver NO analyzer. Prior
to measuring NO in the samples, a series of standard NaN03 solutions were run
from which a standard curve was obtained. Frozen samples of perfusate were
thawed NO was measured as previously describe (Xiao et. al., 1999). In brief,
NO was measured by injection of a 100-pl aliquot of the perfusate into a Sievers
270B NO analyzer (Sievers instruments, Boulder, CO). In this instrument a
stable nitrate and nitrite are reduced to NO. NO is then measured by reaction
with ozone which yields light that is detected by a photomultiplier tube.
Calibration curves were run during each analysis, and individual standard curves
(0-200 pmol) were used to convert NO signals from samples into pmol of NOx.

Isolation of Soluble Protein in Cerebral Blood Vessels: Cerebral artery
homogenates were prepared as previously describe (Pearce et. al., 1997).
Briefly, cerebral arteries were dissected from each (pooled blood vessels from 23 brains) were weighed and homogenized in 1 ml of ice cold N-2hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES, 50 mM, pH 7.0).
Facial arteries were also pooled and prepared in the same manner as the
cerebral arteries. The homogenates were centrifuged for 30 min at 10,000xg.
The supernatant was decanted and centrifuged for 75 min at 180,000 xg. Total
tissue soluble protein content was calculated by spectrophotometric
measurement of soluble protein in a 10 pi aliquot of 180,000 xg supernatant
using a bicinchoninic acid protein assay kit and bovine serum albumin (BSA)
standard obtained from Pierce (Rockford II, USA; Smith et. al, 1985).
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Western Blot Analysis: Western immunoblotting techniques were used to
detect and quantify the relative levels of nNOS in cerebral artery homogenates
from fetal and adult normoxic and hypoxic sheep. We used a modified Western
blot analysis protocol for nNOS described by Tracey et. al.,1994. Soluble protein
samples and recombinant rat nNOS (bNOS) standards (BIOMOL, Plymouth PA,
USA) were prepared in Laemmli buffer (Biorad, Hercules CA, USA) containing
5% 2-mercaptoethanol. Samples and standards were heated to 100° C for 5 min
and separated by 7.5% Tris-HCI SDS polyacrylamide gels (150V, 90 min) and
transferred onto polyvinyldiene difluoride (PVDF) membranes with a semi-dry
transfer cell (15V, 55 min, Biorad). Completion of electroblotting of samples and
nNOS standards was verified by staining the gel overnight with Coommasie blue.
Gels consistently stained negative for protein bands demonstrating that complete
transfer of proteins had occurred. Membranes were blocked for 12 hrs (14 hrs
maximum) at 4° C in blocking buffer containing 10 mM Tris-HCI (pH 7.5)
containing 100 mM NaCL, 0.1% Tween-20 and 6% non-fat dry milk. The
blocking buffer was replaced with fresh blocking buffer containing rabbit anti rat
polyclonal nNOS IgG antibody (BIOMOL) diluted 1:1000 for 1 hr. Membranes
were washed three times (20 min per wash) with washing buffer containing 10
mM Tris-HCI, 2 mM NaCL 0.1% Tween-20 and incubated for 1hr in washing
buffer containing 5% non-fat dry milk and secondary alkaline phosphatase
conjugated antibody (1:1000 dilution, Biorad). Membranes were again washed in
washing buffer three times for 20 min and protein bands were detected by
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enhanced chemiluminescence (ECL) and exposed to ECL film (Amersham
Pharmacia Biotech, Newark NJ, USA). On each gel a molecular weight ladder
(Biorad) was used to confirm the relative molecular weight of nNOS in samples
and nNOS recombinant standards. Sample and recombinant nNOS standards
consistently yielded a single band migrating between the molecular weight ladder
standards of Myosin (199 kD) and b-galactosidase (128 kD). This migration
yields an approximate molecular weight of 155kD in the samples corresponding
to the approximate molecular weight of the rat nNOS recombinant standard of
155 kD.

Quantification of Relative Abundance of nNOS: Densiometric analysis of
autoradiographic films was used to determine relative abundance of nNOS in
cerebral artery homogenates. Plots of optical density vs nanograms of
recombinant nNOS for each western blot were used as a standard curve to
quantify the relative amount of nNOS in each sample. Standard curves were
linear (Fig 3E,F) from 4 to 30 ng of recombinant nNOS standard with a lower limit
of detection of 2.5 ng. The linear equation was used to convert the optical
density of nNOS bands in the samples to ng of nNOS. Relative abundance was
determined simply by the ratio of ng nNOS detected in sample/mg of total soluble
protein.

Statistical Analysis: 2-way ANOVA and Fisher's protected least-significant
difference test were used to analyze the impact of development and chronic
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hypoxia on NE content, abundance of nNOS and stimulation-evoked NE and NO
release. All data were analyzed for heterogeneity of variance by a Cochran's
test. If significant heterogeneity was detected then the data was transformed to
log values and the tests repeated. The effects of L-NAME and SNAP treatment
relative to controls within the groups were determined by paired student's t test.
Comparison of stimulation-evoked NE and NO to basal and the effect of TJX was
also determined by paired t test.

Results
Stimulation-evoked NE and NO Release in Normoxic MCA: Activation of
perivascular nerves in fetal and adult normoxic MCA significantly increased
fractional NE release (Fig. 1A,B). In the same tissues activation of perivascular
nerves significantly increased NO overflow compared to basal release (Fig.
1C,D). In addition, the neuronal toxin TTX completely blocked stimulationevoked NE and NO release in the MCA. In contrast, activation of perivascular
nerves in fetal and adult normoxic FA significantly increased fractional NE
release however, no increase in NO overflow as compared to basal was detected
(data not shown). In the presence of TTX stimulation-evoked NE release in the
FA was blocked. However, stimulation-evoked NO release was unaffected by
TTX as compared to basal release (data not shown).
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Effects of L-NAME and SNAP on Stimulation-Evoked NE Release: The
effects of the NOS antagonist L-NAME and the NO donor SNAP on stimulationevoked fractional NE release from normoxic fetal and adult MCA are shown in
figure 2. To validate the effects of L-NAME and SNAP time controls were used
to insure that stimulation-evoked NE release from adrenergic nerves was
consistent over the experimental time course. Stimulation-evoked NE release in
these time controls was consistent for both normoxic and hypoxic fetal and adult
arteries (data not shown). In the presence of L-NAME, stimulation-evoked NE
release significantly declined in normoxic fetal and adult MCA and this effect was
completely reversed by application of the NO donor SNAP (Fig. 2A,B).
Contrasting MCA from normoxic animals, L-NAME and SNAP no longer had any
effect on stimulation-evoked NE release in MCA from fetal and adult hypoxic
animals (Fig. 2C,D). In the FA L-NAME had no significant effect on stimulationevoked NE release from normoxic or hypoxic fetal and adult FA (data not
shown).

Effects of Development and Chronic Hypoxia on Relative Levels and
Function of nNOS in Cerebral Arteries: As shown in figure 3A, C soluble
nNOS is detected in supernatants from fetal and adult normoxic cerebral artery
homogenates. However, there is no detectable nNOS in the pellet fraction of
cerebral arteries confirming that nNOS is a soluble protein (Fig. 3A-D).
Interestingly the nNOS levels decline in supernatants from fetal and adult hypoxic
cerebral artery homogenates (Fig 3B,D). In contrast to the MCA there is no
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detectable nNOS in supernatants from fetal and adult normoxic or hypoxic FA
(data not shown).
Using the standard curve generated from ng of recombinant nNOS vs
optical density (Fig. 3E,F) we quantified the relative abundance of nNOS per pg
of soluble protein in cerebral artery supernatants (Fig 4A). The relative
abundance of nNOS is similar in both normoxic fetal and adult cerebral arteries.
However, the relative abundance of nNOS in hypoxic fetal and adult cerebral
arteries dramatically declines with no significant difference between hypoxic fetus
and adult (Fig. 4A). Stimulation-evoked NO release normalized to total soluble
protein is not significantly different in normoxic fetus as compared to adult MCA
(Fig 4B). Consistent with the decline in relative nNOS abundance in cerebral
arteries from hypoxic fetus and adults, stimulation-evoked NO release
dramatically declines in MCA from hypoxic fetal and adult sheep (Fig. 4B).

Effects of Development and Chronic Hypoxia on NE Content and Basal NE
release in MCA: Table 1 summarizes NE content in MCA from fetal and adult
normoxic and hypoxic sheep. In the MCA, NE content in the normoxic fetus is
significantly lower as compared to the normoxic adult.

NE content significantly

declined during chronic hypoxia in MCA from fetus and adult animals. In table 2
the impact of development and drug treatment on basal NE release in MCA is
summarized. Exposure to L-NAME and SNAP did not significantly affect basal
NE release these arteries from normoxic or hypoxic animals. Basal NE release
from the MCA was significantly greater in normoxic and hypoxic fetal arteries as
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compared to adult. Chronic hypoxia did not significantly basal NE release in MCA
from fetal and adult animals.
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Figure 1: Measurement of total NE (A,B) and NO (C,D) overflow from
perivascular nerves in middle cerebral arteries (MCA) from normoxic fetal and
adult sheep. Tissues were exposed throughout the experiment to 1CT5 M
deoxycorticosterone, and 10'5 M cocaine. Perivascular nerves were activated for
1 min followed by a 45 min equilibration. Tissues were then treated 1 pM
tetrototoxin (TTX) and nerves were activated again for 1 min. Columns represent
the mean ± SE. *, significantly greater than the basal release or TTX-treated
release, by a paired t-test. (P<0.01; n = 9-11 arteries).

86

(B) Adult MCA

(A) Fetal MCA.
*
0.1 -I

0.1 -I

T

£ c
0

O -g
t o
0 O
>

1

° CD 0.05-

0.05-

LU Q.

*

2

LU
0 Z

o
I

CL

1

0

1

0

(D) Adult MCA

(C) Fetal MCA

*

£
o n.
0 o
>
o

§§

11

i- 3

200 -i

200 n

150-

150-

*
100-

100T
500

T

i

1

50-

J.
T

Basal

I

0

T

Stim

Stim + TTX

87

T

T

T

Basal

Stim

Stim + TTX

Figure 2: Effect of L-NAME and the NO donor SNAP on stimulation-evoked NE
release in fetal and adult middle cerebral arteries (MCA) from normoxic sheep
‘ (A,B) and hypoxic (C,D) sheep. Tissues were exposed to 10*5 M
deoxycorticosterone and cocaine throughout the experiment. Treatment with LNAME and SNAP was carried out as described in the text. Columns represent
the mean ± S.E. ** = significantly different from two other treatments (i.e. S1 and
S3 or S1 and S2) by paired f test (P<0.01). n = 8-12 arteries.
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Figure 3: Representative western blots for nNOS in the high speed supernatant
and pellet fractions (see methods) of cerebral artery homogentates from fetal and
adult normoxic (A,C) and hypoxic (B,D) animals. (E) Representative blot of a
series of recombinant rat nNOS standards demonstrating the change in optical
density from 4-30 ng. (F) Plot of integrated density vs ng recombinant rat nNOS
(n = 16 curves). A standard curve for each blot was used to convert relative
density of nNOS bands in the samples to ng of nNOS for quantification of relative
abundance of nNOS in cerebral artery homogenates (see methods).
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Figure 4: (A) Effect of development and chronic hypoxia on relative abundance
of nNOS per unit of soluble protein in cerebral artery homogenates from fetal and
adult sheep. Abundance of nNOS was determined by western analysis and
expressed as a fraction of blotted soluble protein (see methods), n = 4 - 6 blots
from pooled artery homogentates (see methods). (B) Effect of development and
chronic hypoxia on stimulation-evoked NO release from MCA as a fraction of
soluble protein content. * = significantly different from hypoxic by 2-way ANOVA
with repeat measures and Fischer PLSD test, P<0.05).
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Tablet Time controls establishing consistency of stimulation-evoked fractional
NE release in MCA from normoxic and hypoxic fetal and adult sheep.

Fractional NE release pg/pg content/pulse xlO'6

S1

S2

S3

Normoxic

108 ±32

100 ±24

109 ±30

Hypoxic

112± 16

119 ± 13

108± 16

Normoxic

32 ±4.3

33 ±4.5

34 ±4.1

Hypoxic

48 ±6

52 ±5

50 ± 5.2

Fetus

Adult

Values represent the mean ± S.E. All arteries were treated with
Deoxycorticosterone and cocaine throughout the experiment, n = 11-13 arteries
from 11-13 animals.
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Table 2. Lack of effect of L-NAME (L-nitro-L-arginine methyl ester) SNAP (Snitroso-N-acetyl-DL-penicillamine) on stimulation-evoked fractional NE release in
facial arteries from normoxic and hypoxic fetal and adult sheep.

Fractional NE release pg/pg content/pulse xlO'6

S1

S2
L- NAME

S3
L-NAME +
SNAP

Normoxic

65± 16

63 ± 16.2

67 ± 14.5

Hypoxic

90± 15

99 ±13

92 ±16.1

Normoxic

21.2 ±5.2

22 ± 3.2

24 ±4

Hypoxic

18.2 ±2.7

17.6 ±3

19 ± 3

Fetus

Adult

Values represent the mean ± S.E. All arteries were treated with
Deoxycorticosterone and cocaine throughout the experiment. n= 6-13 arteries
from 6-13 animals.
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Table 3. Effect of development and chronic hypoxia on NE content in middle
cerebral arteries.

NE content (ng/mg tissue)

Normoxic

26 ±6 +

Hypoxic

14 ± 2 +

Normoxic

50 ±8

Hypoxic

25 ±4

Fetus

Adult

* = significantly different from hypoxia : + = significantly different from adult, n =
11-13 arteries from 11-13 animals.
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Table 4. Effect of development and chronic hypoxia on basal NE overflow from
the middle cerebral artery.

Basal NE release (pg/pg content x 10'3)

Control

L-NAME

L-NAME + SNAP

Normoxic

8±1 +

9±2

7 ±2

Hypoxic

8±2+

7±1

6±1

Normoxic

2 ±0.5

2 ±0.3

2 ±0.5

Hypoxic

3 ±0.5

1 ±0.2

2 ±0.5

Fetus

Adult

Values are means ± SE of basal norepinephrine (NE). All arteries were treated
with deoxycorticosterone and cocaine throughout the experiment. L-NAME = Lnitro-L-arginine methyl ester: SNAP = S-nitroso-N-acetyl-DL-penicillamine. + =
significantly different from adult, n = 11-13 arteries from 11-13 animals.
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Discussion
To more fully understand the data in the current study a brief discussion of
the hypoxic model is warranted. The sympathetic nervous system has been
suggested to enable an organism to adapt to stress conditions such as acute or
chronic hypoxia (Rose et. al., 1983; Busija and Heisted, 1984). In mammals, the
fetus in is confined to lowered O2 environment and to compensate for this deficit,
exhibits a high cardiac out put and high oxygen consumption (Lorjin and Longo,
1980). In this study pregnant sheep were maintained at 3,820 m resulting in a
maternal and fetal model of hypoxia that is thought to be one of moderate welladapted hypoxia. The cardiovascular, pulmonary, and hematologic
consequences of high altitude hypoxemia are known and generally viewed as
compensatory responses to hypoxemia (Lambertson, 1968). However, there
appears to be a "threshold" of oxygen deprivation, if exceeded can have
pathological consequences (Longo et. al., 1993). During gestation at 3,820 m
adult and fetal arterial PO2 values significantly decline while arterial pH remains
unchanged, and hematocrit increases to maintain oxygen extraction (Kamitomo
et. al., 1992). Hypoxic fetal weight continues to increase with near-term fetal
weights comparable to control fetuses maintained at 718 m. Fetal morbidity,
mortality, and abortion do not increase during exposure to hypoxia at altitude.
Furthermore, the animals in this study were exposed to the same degree of
hypoxic stress as in our previous studies with arterial PO2 values in adult and
near-term fetuses being nearly equivalent (Buchholz et. al., 1999; Buchholz and
Duckies, 2001). These data suggest that this model serves as one of
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acclimatization to moderate chronic hypoxia where adaptive responses can be
successfully studied.

Hypoxia and Function of Adrenergic and nNOS Nerves: The most interesting
results of this study is that activation of perivascular nerves in MCA from
normoxic fetal and adult sheep caused a significant increase in both NE and NO
overflow compared to their respective basal release. Furthermore, stimulationevoked NE and NO release were antagonized by the neurotoxin TTX.
Consistent with these data, in MCA from normoxic fetal and adult sheep,
stimulation-evoked NE release was antagonized by the NOS inhibitor L-NAME
and this effect was reversed by the NO donor SNAP. In complete contrast to
MCA from normoxic sheep stimulation-evoked NO release and the effect of LNAME was completely abolished in MCA from hypoxic fetal and adult sheep.
Taken together these data suggest that cerebrovascular arteries are unique in
that they contain both adrenergic and nNOS neurons and that acclimitization at
high altitude appears to selectively abolish the function of nNOS nerves. The
conclusions derived from the data in the MCA are strengthened by data derived
from our comparison model, the FA, from both normoxic and hypoxic fetal and
adult sheep. Electrical stimulation increases NE release in the FA with no
increase in NO overflow and there is a complete lack of effect of L-NAME on NE
release in FA. Overall, the data derived from this study are in agreement with
our previous studies suggesting that MCA contains both adrenergic and nNOS
nerves (Buchholz et. al., 1999; Mbaku et. al. 2000). In addition, these data are
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consistent with other published studies suggesting that the cerebrovasculature
contain nNOS neurons (Duckies, 1979; Lee and Sarwinski, 1991; Toda et. al.,
1991).
Given the close proximity of adrenergic and nNOS nerves functional
interaction between these nerves has been a topic of interest (Lee et. al.,2000; Si
and Lee, 2001). Several reports have suggested that NO modulates adrenergic
nerve activity. In rat atria, mesenteric arteries, cerebral cortex and sheep MCA,
stimulation-evoked NE release is inhibited by NOS antagonists (Yamamoto et.
al., 1993, 1997; Montague et. al. 1994; Gironacci et. al. 1997; Buchholz et. al.
1999; Mbaku et. al. 2000). These studies suggest that NO from nNOS nerves
serve to augment adrenergic nerve activity. Indeed, in this current study our data
show that in both normoxic fetal and adult MCA L-NAME significantly inhibits
stimulation-evoked NE release demonstrating the facilatory effect of NO on
adrenergic nerves in the cerebrovasculature. It is interesting to note that despite
the decline in function of the facilatory nNOS nerves during the hypoxic period
stimulation-evoked NE release is not significantly altered in the fetal or adult
MCA (Fig 2). In addition, there is a significant decline in NE content in both fetal
and adult MCA during chronic hypoxia (Table 1). In light low nNOS nerve
function and reduced NE content with no change in stimulation-evoked fractional
NE suggests that adrenergic nerves in fetal and adult may cerebral arteries may
compensate for decline the function of the nNOS nerves and NE content to
maintain their overall function. Further studies are necessary to define the
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mechanisms underlying a sustained function of adrenergic nerves during chronic
hypoxia.
The mechanism underlying the facilatory effect of NO is unclear but there
are a few studies that are beginning to illuminate this process. In superior
cervical ganglion cells NO donors such as SNAP increase Ca2+ current amplitude
and in PC12 cells NO donors increase the sensitivity of intracellular calcium
release mechanisms to Ca2+ (Chen and Schofield, 1995; Clementi et. al., 1996).
Furthermore, these effects are mimicked by the cGMP analog 8Br-cGMP. These
data suggest that NO signaling through the cGMP pathway may elevate
stimulation-evoked increases in intracellular calcium and provide at least one
rational explanation for the effects of NO on NE release in this study.

Hypoxia and nNOS Levels in Cerebral Arteries: What is most novel with the
current study is that high altitude hypoxia seems to abolish the function of nNOS
nerves while not appreciably affecting the function of adrenergic nerves. These
data are consistent with our previous studies demonstrating the effect of L-NAME
on stimulation-evoked NE release is abolished with chronic hypoxia (Buchholz et.
al., 1999). To further our understanding of the impact of chronic hypoxia at high
altitude we measured the relative abundance of nNOS in cerebral arteries in fetal
and adult sheep (Fig. 4A) and expressed stimulation-evoked NO overflow (Fig.
1C,D) as a fraction of total soluble protein (Fig. 4B). When the data are
expressed in this manner a clearer picture emerges. First is in normoxic animals
the relative abundance of nNOS is similar in fetal and adult cerebral arteries.
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Secondly, stimulation-evoked NO release as a fraction of total soluble protein is
also similar in fetal and adult cerebral arteries. Thus, even though total
stimulation-evoked NO overflow in fetal MCA is lower than adult, when this is
corrected for soluble protein content stimulation-evoked NO release is similar in
fetus and adult. These data suggest that the relative nNOS activity in the
cerebral arteries of near term fetuses and adults is similar. Another important
aspect of this study is that the abundance of nNOS in cerebral arteries
dramatically declines during chronic hypoxia experienced at high altitude in both
the fetus and adult (Fig. 4A). Consistent with these data is that stimulationevoked NO release as a fraction of soluble protein also declines with no
significant differences between the hypoxic fetus and adult. Overall the data
suggest that at least one mechanism for the decline in the effect of L-NAME on
stimulation-evoked NE release and NO release is due to a decline in the levels of
nNOS as opposed to alterations in the activity of this enzyme. To our knowledge ,
this is the first study to report such results.
In this study stimulation-evoked NO release as a fraction of soluble protein
and relative nNOS levels as a fraction of soluble protein is similar in the MCA
from the fetus and adult. Interestingly these data contrast another study
demonstrating that nNOS activity in brain homogenates in the presence of
saturating levels of cofactors is greater in adult as compared 14-18 day old rat
pups (Pearce et. al., 1997). These data suggested that change in the function of
nNOS with development could in part be due to changes in the nNOS levels
during prenatal and early postnatal life. Consistent with this idea it has been

102

shown that different hormones which change during pregnancy, and
development alter nNOS levels in the rat brain (Forstermann and Kleinhart,
1995). Overall, the current study suggest that the mechanisms controlling
cerebrovascular nNOS protein levels appear to be near or fully developed in the
sheep near term fetus.

Effect of Development and Chronic Hypoxia on NE Release: There is little
specific information on the impact of development specifically on stimulationevoke fractional NE release. In this study both basal and stimulation-evoked
fractional NE release from MCA is significantly greater in the fetus as compared
to the adult. Thus, during development adrenergic nerve function appears to
decline. Overall the data in this study are consistent with our previous studies
suggesting that adrenergic nerve activity rises just before birth (Buchholz, et. al.,
1999; Buchholz and Duckies, 2001). Moreover, the data are consistent with
rising plasma levels of NE in both rats and sheep (Choi et. al., 1997; Smolich et.
al., 1997). The rise in sympathetic nerve activity before birth is consistent with
the idea that fetus must prepare transition from a highly modulated environment
to the external environment where the animal must depend on its own
mechanisms for modulation vascular reactivity.
In conclusion, we have shown that stimulation-evoked nNOS nerves
augment stimulation-evoked NE release and that during acclimatization to
chronic high altitude hypoxia during gestation the function of these nerves
declines. However, despite the loss of the nNOS nerves adrenergic nerves are
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able to maintain their function suggesting adaptation to high altitude hypoxia. In
addition, we propose that at least one mechanism underlying the decline in
nNOS nerve function is that nNOS levels significantly decline during chronic
hypoxia. The loss of function of nNOS nerves may have consequences for the
distribution of cerebral blood flow during acclimatization at high altitude.
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CHAPTER 4
THE NO/cGMP-DEPENDENT PROTEIN KINASE-1 PATHWAY CONTROLS
INTRACELLULAR Ca2+ RELEASE IN RAT SCO

Abstract
The fate of NO upon release from / into a biological system under normal
physiological conditions involves numerous and wide spread interactions with
other chemical species. One such species is guanylyl cyclase - an enzyme that
drives the synthesis of cGMP which is an important second messenger of the NO
system. In vascular smooth muscles cGMP causes relaxation (see diagram
below) but in neurons cGMP - dependent protein kinase (PKG-1) may be
activated giving rise to a distinct and potentially important reaction pathway. In
this chapter we examine the influence of the NO/cGMP - dependent protein
kinase 1 pathway on the control of caffeine-evoked intracellular calcium ([Ca2+]i)
release in fura-2 loaded SCG cells from adult F-344 rats. Caffeine-evoked [Ca2+]i *
transients were generated over a concentration range of 0.05 to20mM and
expressed as a % of the [Ca2+]i transient generated by 68mM KOI. The NO donor
S-nitoros-N-acetyl -DL- penicillamine (SNAP), and 8-Br-cGMP - a stable analog
of cGMP both significantly increased the potency (reduced EC50) and maximum
effect of caffeine on calcium release when compared to the control. Addition of
KT5823 - a PKG-1 antagonist completely reversed the effects of SNAP and / or
8-Br-cGMP. These data suggest that the NO/cGMP - dependent protein kinase
pathway sensitizes the rayonidine receptors to caffeine. Furthermore, these data
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suggest NO may augment the function of adrenergic nerves by elevating
stimulation-evoked [Ca2+] transients.

Introduction - Evidence of Interaction between Adrenergic
and nNOS Nerves
Thus far, we have evidence that both adrenergic and NOS-expressing
nerves co-exist in cerebral arteries, and that a reciprocal interaction exists
between these two neuron types. For instance, during nicotine-induced relaxation
of pre-constricted porcine basilar arteries, nicotine is suggested to act on
nicotinic receptors on the pre-synaptic adrenergic nerve terminals to release
norepinephrine or a related substance, which then stimulates release of nitric
oxide from the neighbouring nitric oxidergic nerves (Zhang et al., 1998). On the
other hand, our previous data (Mbaku et al., 2003) have suggested that NO,
released from these NOS-expressing nerves in cerebral arteries exerts a
facilitator effect on the adjacent adrenergic nerves function.
There is some studies suggesting that the one underlying mechanism by
which NO can augment adrenergic nerves function is the enhancement of
stimulation-evoked [Ca2+]i transients. For example in rats SCO cells NO donors
such as SNAP and sodium nitroprusside (SNR) enhanced the amplitude of
neuronal Ca2+ transients, which could underlie enhanced exocytotic release of
NE from sympathetic neurons (Chen and Schofield, 1993). In fact it has been
shown that NO induces enhancement of Ca2+ transients via stimulation of cGMP
synthesis (Chen and Schofield, 1995). However, the exact cascade of events
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that occurs and the different agent(s) involved beginning with the NO-induced
cGMP synthesis, all the way to the observed increased release of NE has not
been uncovered. Several theories and speculations have been proposed in the
literature, but only the one involving adenosine diphosphate ribose seems
persuasive.
Cyclic adenosine diphosphate ribose (cADPr) is a potent endogenous
calcium-mobilizing agent synthesized from _-NAD+ by ADP-ribosyl cyclases in
sea urchin eggs and in several mammalian cells (Galione and White, 1994).
Pharmacological studies suggest that cADPr is an endogenous modulator of
Ca2+ -induced Ca2+ release (CICR) mediated by ryanodine sensitive Ca2+ release
channels. The observation that cGMP can stimulate the synthesis of cADPr from
P-NAD+ by activating its synthetic enzyme ADP-ribosyl cyclase, is a novel
discovery. See figure 1 below. In this case it suggests that cADPr may transduce
signals generated by cell surface receptors or gaseous transmitters linked to
cGMP production (Galione et al., 1993).
A second messenger role for cADPR requires that its intracellular levels be
under the control of extracellular stimuli such as NO or cGMP and in fact this has
been shown to be the case. (Galione et al.,1993). Putting all these facts together,
we can visualize a mechanism for the NO facilitation of stimulation-evoked NE
release. Thus:
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Figurel: Illustrates the reaction cascade involved in the synthesis of cADP
ribose following the release of NO. Arrows indicate the direction of the reaction.
NO can activate guanylyl cyclase leading to the synthesis of cGMP from GMP.
Subsequent cGMP-mediated activation of protein kinase G, (PKG-1) leads to
activation of ribosyl cyclase. Activated ribosyl cyclase then converts pNAD to
cADP ribose.
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For a convincing argument that the above reaction cascade involving
cADPr is responsible for the observed NO-mediated facilitation of stimulationevoked NE release, first we need evidence that the NO/PKG-1 pathway controls
intracellular calcium release from the CICR pool and secondly, measure the
cGMP-mediated increases in cADPr. Here we focus on the first part i.e. evidence
linking the NO/PKG-1 pathway to the release of intracellular calcium from the
ryanodine pool.
Therefore we design these studies to examine the possible mechanism(s)
which may underlie NO-induced enhancement of Ca2+ channel currents first in
sheep and then in rat superior cervical ganglion (SCG). We explored an
interesting property of the cADP-ribose-induce Ca2+ release, i.e. its synergism
with Ca2+ induced Ca2+ release, already demonstrated in sea urchins oocytes
(Lee, 1993,). This synergy was revealed by experiments with caffeine, a drug
known to act by lowering the threshold of the CICR (Meissner 1994). When an
NO donor was administered together with the xanthine the overall effect was a
doubling of the already considerable response to caffeine alone, which was
much greater than the sum of the latter with the modest NO-initiated response,
which by itself was hardly appreciable by the fura-2 approach. We measured
caffeine-evoked calcium transients from different caffeine solutions and
expressed the results as a ratio of the transient due to 68mM KCI. We compared
caffeine-evoke calcium transients measured in the presence of SNAP, 8-BrcGMP to both the controls (no drug) and those measured when the cells are
incubated in KT5823. We also compared the responses of fura-2-loaded rat SCG
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cells to 68mM KCI and 10mM caffeine in a calcium free medium, with the
responses obtained in a medium containing 2mM Ca2+. Two hypotheses were
addressed; (1) Caffeine selectively release calcium from the intracellular stores particularly the CICR pool, (2) NO/cGMP-dependent protein kinase 1 pathway
reinforces caffeine at the ryanodine receptor and controls the release of calcium
from the ryanodine pool of the intracellular stores.

Materials and Methods
Healthy 6-month fisher F344 male rats with an average weight range
between 350 to 425 g were randomly separated into six groups of 16 rats each.
Two control groups, one group was used for the control dose-response curve
and the other used to establish the selectivity of caffeine using a calcium free
medium. There were four treatment groups organized as follows: (16 rats each
used to monitor the effect of SNAP, and SNAP + KT5823), (16 rats each for the
effects of 8-Br-cGMP, and 8-Br-cGMP + KT5823). At the beginning of the
experiment, the rats were euthanized in a gas chamber for approximately 1
minute with 95% C02 / 5% 02.

Tissue Extraction
The superior cervical ganglia are located between the angles of bifurcation of the
common carotid arteries, and are wedged between the forks made by the internal
and external carotid arteries. From the apex of the thorax, a branch of the vagus
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nerves runs parallel to (and intimately with) the common carotid artery and is
physically attached to the SCG at the base of the skull.

Ganglion Preparation
Immediately following sacrifice, the SCGs were removed by micro dissection and
placed in glass plate containing ice-cold Tyrodes solution. The Tyrodes solution
contains the following constituents: (in moles) 0.15 NaCI, 0.004 KCI, 0.002
CaCI2, 0.002 MgCI2, 0.01 N-2 hydroxyethylpiperazine-N-2-ethansulfonic acid
(HERBS), and 0.01 dextrose (pH adjusted to 7.4). After all extractions were
completed, the SCGs were desheath, trimmed of projecting axons and were
nicked randomly in several locations to increase surface area for enzyme
digestion. The SCGs were then placed in testubes containing 5ml of Earle’s
digestion buffer and incubated for 45 min at 34°C in a special water bathe with
adjustable oscillator, set at a speed of 50. The Earle’s digestion buffer contained
0.5mg of trypsin/ ml (there are approximately 6000 units / ml), 1mg of
collagenase D / ml, 0.01 mg DNAse-1 type IV / ml, 0.02M HEPES, 0.01 dextrose
and 0.01 M NaHCOs (adjust the pH to 7.4 with NaOH / HCI). After digestion, the
Earle’s buffer was immediately neutralized by adding 5ml Hanks culture solution
to the testubes. Hanks culture solution contains 10% fetal calf serum, 0.0013M
CaCI2, and 0.005M HEPES (pH adjusted to 7.4). The cells were then caused to
dissociate from the SCG and dispersed by shaking the testubes repeatedly (35
times). A 5min spin at 600 r.p.m allowed the cells to resettle at bottom of the
testubes. This procedure was repeated once to rid the culture solution of any
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remnants of the digesting solution. The cells were then resuspended in a 0.5ml
Hanks culture solution and plated on cell-tak pre coated 22mm square glass
plates over night. The glass plates were especially prepared for this purpose by
allowing telflon rings dipped in silicon gel to dry on special glass slabs. The next
day (in about 12hours) healthy SCG cells are held firm to the glass plate by cell
tak and are ready for calcium measurements.The whole assembly is called a
coverslip. See figure 2 below.

A cover slip
22mm transparent
glass slab
Teflon ring glued to the--glass slab with Svlgard

▲

Cell tak - coated surface in which SCG
cells are incubated

Figure 2: This is a diagrammatic representation of a cover slip. The Teflon ring is
secured on the transparent glass slab with silicon gel - and allowed to harden.
The space inside the ring is coated with cell tak that would then hold incubated
SCG cells in place during the experiment run.
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Measurements of Intracellular Calcium in SCG Cells
Coverslips containing SCG cells were loaded with 10uM fura-2 for 20 minutes
after which they were mounted in to the perfusion chamber located on the stage
of the Nikon inverted microscope. Connected to the Nikon microscope are
components of the universal imaging system that include a mercury / xenon
vapor lamp source, a Hamamatsu imaging camera and a motorized rotating filter
wheel controlled by a Sutter II, and contains special light filters that would
transmit electromagnetic radiation only at 340nm and at 380nm when the lamp
gate is opened during the Ca2+ measurement runs. The universal imaging
system runs on a soft ware called Metaflour 4.0 which inputs directly in to excel
from where all data can be saved electronically or copied. The perfusion
chamber allows rapid introduction and wash-off of drugs in and out of the
coverslips. Once mounted on to the perfusion chamber, healthy SCG cells were
located using the focus adjustments on the scope. An ideal SCG cell would be
larger than the biggest glial cells, looks bright green under the camera after fura2 absorption, appears smooth on the surface like pebbles in a river and firmly
secured to the surface of the plate. The cell(s) of interest within a given field of
the microscope were focused upon so as to obtain a nice bright image on the
monitor. Light from the lamp source illuminated the cells and the fluorescent
excitation occurred alternately as the Sutter II oscillates the filter wheel placing
the 340 filter in front of the lamp gate at one instance and then the 380 filter at
another. This pattern permits the 340 and 380 images to be collected every 500
millisecond and every second each.
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Measurement of [Ca2+]i is described in detail by various authors
(Negelescu and Machen, 1990; Werth et. al., 1996; Buchholz et. al., 1996). In
these experiments [Ca2+]i measurements will be made with a Universal Imaging
system (ETM-systems, Irvine CA). Fura-2 in the cells is illuminated with a 100
watt Hg vapor lamp at 340 and 380 nm. Fluorescence emission wavelength, 510
nm, is selected with a 480 nm barrier filter and records are corrected for
background.

The 340/380 ratio of intensity of fluorescence at 510 nm is

calculated by computer. Ratios are converted to free Ca2+ at a rate of 500 msec
by iterative fit to the standard equation [Ca2+]i = Kd (R-Rmin)/(Rmax-R) where Rmin
is the minimum intensity ratio at 512 nm when Ca2+ is at zero concentration, R max
is maximum intensity ratio at 512 nm when Ca2+ is at saturation levels and Kd is
the dissociation constant of Fura-2 for Ca2+. The values Rmin and R max and Kd
are determined by multiple calibrations. Our calculated Kd of 252 ± 30 nM
compares well with other published values of approximately 200 nM (Negelescu
and Machen, 1990). Dr. John Buchholz, the my principal research advisor has
over 10 yrs experience with this technique
To examine the selectivity of caffeine, in releasing Ca2+ from the
intracellular stores (the ryanodine or CICR pool), we measured Caffeine as well
K+-evoked transients in both a calcium free medium and in a medium containing
2mM Ca2+. To examine the synergy between CICR and NO/PKG-1 pathway we
chose to use caffeine - a drug known to lower the threshold of the former. We
measured caffeine-evoked calcium transients over a series of Caffeine standard
solutions ranging from 0.05mM to 20mM. The results, expressed as a % of the
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68mM K+ -evoked calcium transients, were plotted against the log of caffeine
concentrations. The resulting sigmoid curve served as a control against which to
compare similar sigmoid curves obtained after incubating the SCG cells with
various drugs. (SNAP, 8-Br-cGMP, and KT5823)

Results
Selectivity of Caffeine
When a high concentration of potassium ions (68mM KCI) was introduced
to fura-2A-loaded SCG cells in a medium containing 2mM Ca2+, the cells
underwent a depolarization and calcium influx through voltage sensitive calcium
channels and trigger CICR. A transient was observed which represented the brief
increase in intracellular calcium due to both influx and CICR. When a similar
activation with 68mM K+, was carried out in a calcium-free medium, there was no
transient at all. However, when a10mM caffeine was introduced, still in the
calcium-free medium, a smaller but conspicuous transient was observed. Upon
activation again with 68mM KCI, no transient was observed. Once the calciumfree medium was replaced with a medium containing 2mM Ca2+, and activated
again, a K+-evoked transient reappeared just as it was before the calcium-free
medium was introduced. Caffeine on the other hand showed an identical
transient in both the calcium-free medium and the medium containing 2mM
Ca2+.
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Figure 3: Shows that Caffeine is selective in releasing Ca2+ from the intracellular
stores. (A) - Activation of fura2a-loaded SCG cells with 68mM K+ in a medium
containing 2mM Ca++ gave a calcium transient. (B) - In a zero Ca2+ medium, the
cell responded to 10mM Caffeine with another transient. (C) - No response from
the cell when activated with 68mM K+ in a calcium-free medium. (D) - A 2mM
Ca++ - medium restored the response upon activation with 68mM K+.
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Caffeine Dose Response
Caffeine, a drug known to lower the threshold of CICR, elicited calcium
transients in fura2A-loaded SCO cells that were dependent on caffeine
concentration. Our lower limit of detection was 0.05mM caffeine. When caffeineevoked calcium transients were expressed as a % of 68mM K+-evoked transient,
and the results plotted against the log of caffeine concentration, a sigmoid curve
was obtained. The average linear range fell between 1 to about 10mM caffeine,
whereas the plateau section of the curve was generated by caffeine
concentrations greater than 20mM. The maximum caffeine-evoked calcium
transients averaged about 50% of the 68mM K+-evoked transients.

Effects of SNAP, 8-Br-cGMP and KT5823
When fura2A-loaded rat SCO cells were incubated for 10min each in
50pM SNAP or 100pM 8-Br-cGMP or 50pM SNAP+10pM KT5823 or 100pM 8Br-cGMP+IOpM KT5823 and activated with a series of caffeine standard
solutions as described above in the caffeine-dose-response section, results were
as follows. Both SNAP (an NO donor) and 8-Br-cGMP (a stable cGMP analog)
increased the potency and maximum effect of caffeine when compared to the
control. Maximum effect of caffeine increased from 50% of 68mM K+-evoked
calcium release in the controls to 90% of K+-evoked calcium release in the
presence of SNAP or 8-Br-cGMP. The PKG-1 antagonist KT5823 completely
reversed the effects of both SNAP and 8-Br-cGMP on caffeine-evoked calcium
release. The effects of these drugs were also expressed as PD2-values to
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expose their impact on the potency of caffeine-evoked calcium release.
Again, both SNAP and 8-Br-cGMP significantly increased the PD2 values
(reduce EC50 and increase potency) of the caffeine dose response. Addition of
the KT5823, completely reverse the increase in PD2 values.

£ T
S * 1201
o 2
cc E
_

00

— Control

100-

E <0

■J 5
(O .o
O O0)

o
i2
d>
.E

^
-a
w
«
0)
o.

<u x
in

50/yM SNAP

8 0-

■a— 100 yt/M 8Br-cGMP

6 04 0'

— 50 /yM SNAP+ 10/yM
KT5823

2 O'

— 100 yuM 8Br-cGMP + 10 yc/IV
KT5823

03 ^

o

0

-1

-5
Log

0

[Caffeine]

Figure 4: A plot of caffeine-evoked calcium release expressed as a percent of
the calcium released upon 68mM K+ stimulation, versus the log of caffeine
concentration. 50pM SNAP and 100pM 8-Br-cGMP (pink and green lines
respectively) increased the both the potency and maximum effect of caffeine with
respect to the control (deep-blue line). The effects of SNAP and 8-Br-cGMP were
equally abolished upon 5min incubation in 10pM KT5823 - a PKG-1 antagonist.
This demonstrates a synergy between NO/PKG-1 pathway and Ca2+-induced
Ca2+ release whose threshold is known to be lowered by caffeine.
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Figure 5: Represents the PD-2 values from the plot of caffeine-induced Ca++
release versus the log of caffeine concentration (above). 100pM 8-Br-cGMP and
50pM SNAP significantly raised the PD-2 values (increased potency) when
compared to the control. KT5823 abolished the effects of SNAP and 8-Br-cGMP
suggesting that the NO/cGMP-dependent protein kinase-1 pathway plays a role
in controlling intracellular calcium.
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Discussion
Caffeine Selectively Released Calcium from the Intracellular Stores
The observation that caffeine is selective in releasing calcium from the
ryanodine pool of the intracellular stores is very crucial in that such a property
has rendered the xanthene a suitable probe with which to examine the synergism
between CICR and the NO/PKG-1 pathway and has strengthened the rationale
of the argument put forth by this study. When fura-2AM-loaded SCG cells are
suddenly exposed to a high concentration of K+ in the perfusion chamber, the
cells undergo a depolarization. Calcium influx through activated voltage-sensitive
calcium channels and triggers CICR. The resulting transient represents the brief
increase in intracellular calcium due to both influx and the issuing CICR. As the
intracellular calcium buffering systems (Mitochondria, SERCA, Ca2+ binding
proteins, Na7Ca2+ exchanger and PMCA) mob up the extra calcium released into
the cytosol, the signal dies away giving the sharp peak observed. When the cells
were again activated with high [K+] in a calcium-free medium, there was no signal
despite the possible activation of the voltage sensitive Ca2+ channels on the cell
membrane. It turned out that in the absence of extracellular calcium, no influx
and therefore no CICR occurred so that the cytosol experienced no increase in
[Ca2+]i. On the other hand, a10mM caffeine solution was able to illicit a transient
in each media. Of particular importance is the fact that, the caffeine -evoked
transients observed in the calcium free medium were very similar in sizes and
were comparable to the transients obtained in a medium containing 2mM Ca2+ strongly suggesting that caffeine selectively release calcium from the intracellular
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stores. Moreover, it has been shown that Caffeine or cADPr acts co-agonistically
with Ca2+ to potentiate Ca2+ release through the ryanodine receptor (Tanaka and
Tashjian Jr. 1995). Armed with the facts that caffeine is selective for intracellular
calcium stores and that it is a co-agonist to Ca2+ in CICR, we then applied those
observations to the next step. That is, to examine the effects of agonists and
antagonists of the NO/PKG-1 pathway on the control of intracellular calcium
release - particularly from the ryanodine pool.

Caffeine Dose Responses
As mentioned before, Caffeine is a drug known to lower the threshold of
calcium induced - calcium release (CICR) in sea urchins and other mammalian
cell types (Meissner 1994). The sigmoid curve obtained in figure 4, by plotting
caffeine-evoked calcium transients expressed as a % of K+ transient showed
three important characteristics of caffeine-induced calcium release - namely the
potency (EC50), the linear range, and its maximum effect on calcium release.
The NO donor SNAP and the stable cGMP analog 8-Br-cGMP each significantly
increased both the potency and maximum effect of caffeine-evoked calcium
release after an incubation period of 10min. A possible explanation for these
observations is that during the 10min incubation period NO triggered a reaction
cascade leading to the synthesis of cGMP, and subsequent activation of PKG-1.
Activated PKG-1 then phosphorylates ADP ribosyl cyclase or a regulator of this
enzyme resulting in the subsequent generation of cADPr, which then caused the
observed release of intracellular calcium - see figurel above (Willmott et al
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1996). Further more upon alOmin incubation with the PKG -1 antagonist
KT5823, the effects of either SNAP or 8-Br-cGMP were completely reversed.
These results are consistent with previous reports that NO induces enhancement
of Ca2+ currents via stimulation of cGMP formation (Chen and Schofield 1995)
and suggest that the NO/PKG-1 pathway reinforces caffeine and therefore CICR
at the ryanodine receptor. Although this has been shown to be the case in sea
urchins oocytes (Lee 1993), to the best of my knowledge this would be the first
time to link NO/PKG-1 pathway to intracellular calcium release in neurons.
It might well be possible that the observed NO-induced enhancement of
Ca2+ channel currents resulted from stimulating the formation of cGMP, which in
turn, activated cGMP-dependent protein kinase, leading to Ca2+ channel-protein
phosphorylation (Butt et al. 1993, Hemmings et al 1989, Paupardin-Tritsch et al
1986, Chen C., and Schofield G.G., 1995). Nonetheless, consistent with our
hypotheses, the main observation in this study is that the NO/PKG-1 pathway
plays a role in the control of intracellular calcium release, possibly via stimulation
of cADPr synthesis - cADP ribose haven been shown to mobilize intracellular
calcium. Supposed that the reported NO-induced enhancement of Ca2+ channel
currents and /or the blockade of NE-induced inhibition of Ca2+ currents were
expressed at the sympathetic nerve terminal so as to enhance intracellular Ca2+
mobilization. Then, such an effect could underlie the NO-mediated enhanced
exocytotic NE release from adrenergic nerves (Chen and Schofield 1995). By the
same token, the observed synergy between CICR and the NO /PKG-1 pathway
would enhance NE release if expressed at the adrenergic nerve terminal. In fact,
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given the structural apposition between these two neuron types in cerebral
arteries as well as numerous evidence of functional reciprocal interactions
including our present observations and previous publication (Mbaku et al. 2000),
we (the authors) suggest here that such could be the mechanism by which NO
enhances stimulation-evoked NE release from sympathetic nerves in cerebral
arteries. An understanding of this mechanism by which endogenous NO
enhances adrenergic function in cerebral arteries is a giant step toward
identifying the physiological significance of the interaction between sympathetic
and nNOS neurons. The role of these two neuron types may be minimal at
normal physiological conditions but during severe hypertensive crisis,
sympathetic nerve discharge could blunt blood flow and protect vital organs
(against elevated CSF pressure; Brashear and Ross 1970; Johnston, et al.,
1971). In addition, sympathetic activation during extreme hypertension could
also reduce blood flow and protect against the disruption of the Blood Brain
Barrier (Heistad and Marcus 1979). All these facts put together along side with
our present observation that the NO/PKG-1 pathway controls the intracellular
calcium release in adrenergic ganglion cells could further be explored for a
possible pharmacological intervention in case of a disease involving cerebral
perfusion.
The question whether PKG-1 also phosphorylates a calcium channel in
addition to stimulating the synthesis of cADPr in neurons, remains open for future
investigation - although phosphorylation has been reported (Butt et al 1993
Hemmings et al 1989, Paupardin -Tritsch et ah 986). At this point however,
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additional experiments would be needed to confirm whether cADPr is the second
messenger next in line following the activation of PKG-1. Even the events leading
to intracellular calcium release once cADPr is synthesized remained illusive
(sketchy) and - addressing such issues would be an important future endeavor.
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CHAPTER 5
SUMMARY AND CONCLUSIONS

Summary
Our long-standing interest in understanding cerebral circulation and its
regulation has enabled us to design and perform the various studies discussed
above (chapters 2, 3 and 4). We saw that the regulation of cerebral perfusion fell
in two categories - namely the intrinsic and extrinsic control systems. The
intrinsic controls which include: neuronal cortical activity, blood gases,
adenosine, extracellular potassium ion concentration, auto regulation and the
endothelium all tend to dominate the control of minute by minute regional blood
flow. On the other hand, extrinsic controls which include circulating hormones
(NE, angiotensin II, Epinephrine, Vasopressin and Atria naturetic peptide), and
nerves (adrenergic and nNOS nerves) do not appear to be involved with the
minute by minute regulation - rather, these controls influence the over-all
cerebral blood flow. Each of these individual control factors is very important in
their own place and their collective contributions ensure the well being of the
animal. However, our studies have laid much emphasis on the neuronal control
system partly because reports have shown that adrenergic nerves might become
significant contributors under certain severe stress conditions such as severe
hypertension.
Within the neuronal control system, our interest has focused all along on
the interaction between its components - Sympathetic nerves interacting with
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nNOS nerves and vice versa. Specifically, in chapter 2 we examined the nature
of this interaction - which up to this point has been controversial due to
discrepancies as to what direction (inhibition versus potentiation) does NO drives
sympathetic nerves function. In chapter 3, having established the nature of such
an interaction, we then examined both the developmental changes (going from
fetus to adult) and adaptational changes (from normoxia to chronic high altitude
hypoxia) in the function of nNOS-expressing neurons in cerebral arteries. Lastly
in chapter 4 we examined the mechanism by which NO enhances NE exocytosis
from the sympathetic nerves in cerebral arteries.

Nature of the Interaction between Sympathetic and Adrenergic Nerves
Beginning with studies designed to examine the nature of the interaction
of sympathetic nerves with nNOS neurons, we used normoxic adult sheep middle
cerebral arteries to measure stimulation-evoked NE and NO release. We
measured stimulation-evoked NE release in the presence of a NOS inhibitor LNAME and the NO donor SNAP. The facial arteries which have not been
reported to contain nNOS nerves were used as a comparison model. The results
revealed that MCAs were unique in that transmural nerve stimulation resulted in
an overflow of both NE and NO. Whereas in the FA - a representative artery,
field stimulation resulted only in NE overflow. A 10|iM L-NAME significantly
increased stimulation-evoked NE release in MCA and this effect was completely
reversed by 25pM SNAP solution. L-NAME had no effect on stimulation-evoked
NE release in the FA. However, SNAP significantly increased stimulation-evoked
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NE release in adult FA, raising the prospect that adult FA might have retained
their sensitivity to NO despite the absence of a neuronal source. These results
suggest that unlike the FA, in the MCA there are sympathetic and nNOS nerves activation of which resulted in an overflow of their respective transmitter. Further
more, the results also suggested that in MCA, nNOS nerves function to release
NO which diffuses to facilitate the release of NE from the adjacent adrenergic
nerves.

Effects of Development and Chronic High Altitude Hypoxia on nNOS Nerve
Function in Cerebral Arteries
Haven revealed the function of nNOS nerves in cerebral arteries, we took
these observations one step further and examined the impact of development
and chronic high altitude hypoxia on the ability of nNOS nerves to modulate
adrenergic function. First we tested the effect of tetrodotoxin (TTX) - a neurotoxin
on stimulation-evoked transmitter release in order to strengthen the assertion
that the source of NO in our experimental tissues is excitable (neurons) and
which appeared to be present only in cerebral arteries. Then stimulation-evoked
NE release measured in the presence of 10pM L-NAME, and / or 25pM SNAP
were performed in all tissue categories (i.e. normoxic fetal / adult MCA and their
corresponding FA, plus hypoxic fetal / adult MCA as well as their corresponding
FA). In addition we measured the relative abundance of nNOS in all artery
categories.
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The results showed that showed that activation of perivascular nerves in
normoxic fetal and adult MCA yielded an overflow of both NE and NO and upon
30min incubation with TTX, stimulation-evoked NE and NO release were
completely abolished. Furthermore, L-NAME significantly decreased stimulationevoked NE release in normoxic fetal and adult MCA and these effects were
completely reversed by SNAP. Neither L-NAME nor SNAP had any effects on NE
release in hypoxic arteries and there was no response to L-NAME or SNAP from
the FA as well. This observation that both L-NAME and SNAP have no effect on
stimulation-evoked NE release from hypoxic and/or facial arteries is reliable due
to a large N-value, but contradicts the previous results in which SNAP tend to
induce a significant NE overflow in FA. This discrepancy may be the pitfall of a
low N-value in our earlier publication.The relative abundance of the nNOS protein
was similar in normoxic fetal and adult tissues, but significantly declined
compared to hypoxic tissues. A similar pattern was observed when stimulationevoked NO release normalized to unit mass of soluble protein in normoxic
tissues were compared to hypoxic tissues. All these observations put together
suggest that in the MCA, there are two types of neurons (adrenergic and nNOSexpressing), and that activation transmural nerves would result in an overflow of
their respective transmitters. The NO in our experimental tissues comes from an
excitable source and this is very likely to be neuronal since stimulation-evoked
NO release was completely abolished by TTX. In cerebral arteries, NO released
by nNOS neurons enhance stimulation-evoked NE release from the adjacent
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adrenergic nerves. During chronic high altitude adaptation, the function of nNOS
nerves declined at least in part due to the decline in nNOS expression

Mechanism by which NO Enhances Sympathetic NE Exocytosis in Cerebral
Arteries
In this last section of my research we used the fisher F344 rats instead of
the traditional sheep model purely for technical reasons. To examine the ability of
NO to mobilize intracellular calcium, we chose to use caffeine - a drug known to
lower the threshold of CICR and measured changes in intracellular calcium
concentration using Microfluorometric techniques (Calcium imaging see appendix
1). First we measured calcium transients triggered by 68mM K+ and 10mM
caffeine first in a calcium-free medium and then in a medium containing 2mM
Ca2+ in order to establish the selectivity of caffeine in releasing calcium from
intracellular stores. Then we measured caffeine-evoked calcium transients in
fura-2AM-loaded SCO cells over a series of caffeine standard solutions expressing the results as a % of K+-evoked transient and plotting it against log of
caffeine concentration, we obtained a sigmoid control curve whose maximum
effect, EC50 and linear range were noted. Using 10pM SNAP, 100pM 8-BrcGMP and 10pM KT5823 we examined the effects of NO / PKG-1 pathway on
caffeine-evoked calcium transients. The sigmoid curves obtained following a
10min incubation of fura-2AM-loaded SCG cells with each of the following drugs;
SNAP, SNAP+KT5823, 8-Br-cGMP, and 8-Br-cGMP+KT5823 revealed the
effects of NO / PKG-1 pathway. Results suggested that extra-cellular calcium is
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required for K+-evoked but not caffeine-evoked calcium transients - suggesting
that caffeine is selective for intracellular stores. Another important observation is
that both SNAP and 8-Br-cGMP significantly increased the potency as well as the
maximum effect of caffeine-evoked calcium release and these effects were
completely reversed by KT5823. When put together these results suggest that
the NO / PKG-1 pathway controls intracellular calcium release - particularly from
the ryanodine pool.

Overall Comments
We have presented strong evidence in favor of the hypothesis that NO
released from nNOS nerves in sheep cerebral arteries, exerts a positive
modulator effect on the function of the neighboring adrenergic nerves during
normoxia conditions. However, in the course of adaptation to chronic high
altitude hypoxia, the modulation by nNOS neurons on Sympathetic nerves is lost.
This lost of nNOS function is due, at least in part to the decline of nNOS
expression with chronic hypoxia and may constitute an adaptive mechanism for
the animal to cope with the stress conditions.
We have also observed that the NO/PKG-1 pathway reinforces caffeine
at the ryanodine receptor and this suggest a role in the control of intracellular
calcium release. More experiment would have to be done in order to confirm the
part played by cADP ribose and / or the initiation of its synthesis by PKG-1 in the
[Ca2+]i mobilizing process. Nonetheless, our data is very consistent with the
proposed mechanism which includes the following: NO-*—adenylyl
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cyclase->-^->->cGMP-^-^->->cGMP-dependent protein kinase
1-^->->-^ribosyl cyclase->->-^-^cADP ribose. See figure 1 in chapter 4.

Conclusions
My research has contributed greatly not just to the field of Pharmacology
but science as a whole. Thanks to our data, new knowledge about the
components of the neuronal control system of cerebral blood flow is now
available. The facilitation of adrenergic nerve function by nNOS neurons, the
adaptive decline in nNOS expression during chronic hypoxia and the mobilization
of intracellular calcium by NO/cGMP - dependent protein kinase -1 can further
be explored for a possible pharmacological intervention in case of severe
hypertension, stress or any other disease state involving cerebral circulations.

Suggestions for Future Studies
In chapter 3, we showed that the decline in nNOS-nerve function during
chronic hypoxia is due at least in part to a decrease in nNOS expression.
However, the activity of the enzyme could also have changed with chronic
hypoxia - raising the prospects that the observed decline in nNOS-nerve function
could be the sum of individual contributions from different factors. It would require
additional studies to address this issue and to elucidate the full impact of chronic
hypoxia on the NO system. A reasonable experimental approach would include
first, the separation of eNOS and nNOS from cerebral artery homogenates. This
can be easily done by centrifuging artery homogenates at 10 K-g for 30min and
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then spinning the resulting supernatant at 180 K-g for 75min - to obtain a final
supernatant, which would be very rich in nNOS. As for the particulate eNOS,
most of it would have been trapped in the pellet at 10 K-g. Secondly, by reacting
[3H]L-arginine with fresh artery extracts (supernatant) in an abundance of the
various NOS co-factors, means that any accumulation of [3H]L-citrulline would be
strictly due to nNOS activity only. To ensure maximum rate of nNOS activity
during this assay, NO must not be allowed to accumulate and should be removed
with a thiol or hemoglobin: (recall that NO exerts negative feed back inhibition on
NOS such that when present, the L-citrulline synthesis would be non-linear and
therefore difficult to characterize). Before collecting any such data, the relative
abundance of nNOS must be calculated per unit soluble protein - so that equal
amounts of nNOS units from hypoxic and normoxic homogenates would be used
to determine changes in the enzyme activity. Any significant changes in the rate
of [3H]L-citrulline accumulation when compared to normoxic controls should
reflect changes in enzyme activity with respect to hypoxia acclimatization.
The question whether PKG-1, in addition to activating ribosyl cyclase can
also phosphorylate a calcium channel on an adjacent adrenergic nerve to cause
influx and a subsequent increase in [Ca2+1i remains an issue. In this respect,
future experiments are warranted to study phosphorylation of an external Ca2+
channel by PKG-1 and to determine the physiological significance of such a
process. An experimental setup to achieve this would involve activation of PKG1
with the NO donor SNAP or 8Br-cGMP and inhibition of PKG1 with KT5823. This
procedure would presumably enhance or antagonize cADP ribose synthesis.
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Using these molecular tools while simultaneously measuring Ca2+ channel
activity via patch clamp techniques, would allow the measurement of Ca2+
channel activity with respect to the controls.
In chapters 4, we showed that the NO/PKG-1 pathway controls
intracellular calcium release. However, it remains to be confirmed that the
NO/PKG-1 pathway is indeed altering the intracellular levels of cADP ribose. This
issue can be addressed by examining the effects the NO donor SNAP or 8BrcGMP on the actual intracellular levels of cyclic ADP ribose. We would be
expecting the levels of cADP ribose to be elevated in the presence of SNAP and
8Br-cGMP-an effect that should be blocked by the PKG1 antagonist KT5823.
Intracellular levels of cADP ribose could be measured indirectly via Ca2+
release. That is, Ca2+ release elicited by known amounts of authentic cADP
ribose is used to construct a calibration curve for cADP ribose. The amounts of
cADP ribose in tissue homogenates are determined by comparing the Ca2+
release activity induced by a fraction of tissue homogenate with the calibration
curve. Any link between the activation of NO/PKG-1 pathway and a resulting
increase in intracellular concentration of cADP ribose would greatly strengthen
our hypothesis since the latter has been shown to mobilize intracellular calcium.
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APPENDIX
THE LOGIC IN MICROFLUOROMETRIC TECHNIQUE
Microfluorometric techniques for measurement of intracellular calcium
employ a dye to examine the spatial and temporal distribution of Ca2+ ions within
living cells. Several dyes are available (e.g. fluo-1, lndo-3) butfura-2AM, in
addition to its fluorescent properties, meets the criteria of a relevant probe for
intracellular calcium measurement in that it is water soluble, non toxic, easy to
calibrate and forms a simple 1:1 complex (linear relationship) with Ca2+. Fura2AM absorbs electromagnetic radiations mostly at 340nm when bound to Ca2+
but when in a Ca2+ free form, most absorption occurs at 380nm. The emission
intensity is at 500-51 Onm. Thus when the dye is in “free” form and activated at
380 nm, the emission intensity at 510 is high and the emission intensity at 510
nm is low when activated at 340nm. When the dye is in the Ca2+ bound form the
emission intensity at 510 nm is low when activated at 380 nm and high when
activated at 340 nm. Thus the ratio of emission intensity i.e. I510 (340) /1510 (380)
will increase progressively as the dye bind Ca2+.
Mathematical relation between the measured fluorescent intensity and [Ca2+]i
The key to understand microfluorometry as it is applied to calcium imaging
lies in the derivation of the equation that describes the linear relation between the
fluorescence intensity (from the dye) and the concentration of the target ion Ca2+ in this case. Thus:
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Where F is the detected emission intensity, S is the proportionality coefficient, D
is the concentration of the fluorescence species, and O is the offset factors
introduced by the instrument (this could be autofluorescence from the lenses in
the optical pathway or the biological specimen examined).These offsets are
neutralized by subtracting fluorescence background (obtained prior to data
collection) from the raw fluorescenct images. Hence the fluorescence without the
offsets is given by;
F, = SXD....(1)
At steady state, the dye and its target ion (Ca2+) are in equilibrium. This is
represented by the following equation;
Df + T —> Db

Kd = (DfT)/Db....(2)
Where Dfis the concentration of the free fluorescent dye, Db is the concentration
of the bound fluorescence dye, T is the concentration of the target species and
Kd is the dissociation constant for the reaction. Expanding equation (2), to
represent each of the fluorescence species;
Ffx = SfXDf

= Sbx Db
For total measured fluorescence;
F\- Ffx + Fbx
Fx = SftDf + Sbx Db
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Since we are dealing with a ratiometric dye, there are two excitation wave
lengths

and

corresponding to 340 for Db and 380 for Df. Hence the above

equations can be rewritten as
Fi - SfiDf + SbiDb

5a

F2 “ Sf2Df + Sb2Db

5b

Taking the ratio of measured fluorescence intensities, we obtained;
R = Fi / F2
R - (Sf|Df + SbiDb) / (Sf2Df + Sb2Db)

(6)

Solving equation (2) for Db, the concentration of the bound dye gives;
Db = (DfT) / Kd........(7)
Substituting Db into equation (6) and solving for T, the concentration of the target
molecule we end up with:
T = Kd { [R - (Sf1/ Sf2)] / [(Sbi/Sb2) - R]} {Sf2/Sb2}.....(8)
In the above equation, there two unknowns (T & R) in one equation - this makes ’
the equation unsolvable. Therefore we have to determine R, since S is a
constant whose value depends on the instrument itself. To determine R, the
proportionality constant, four measurements have to be made. Thus;
-

F1L = I510 340nm at zero Ca2+, or lowest concentration of target molecule.

-

F2L = I510 380nm at zero Ca2+, or lowest concentration of target molecule.

-

F1H = I510 340nm at saturating Ca2+, or highest concentration of target
molecule.
F2H = I510 380nm at saturating Ca2+, or highest concentration of target
molecule.
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1.1) Important assumptions: at zero Ca2+, the concentration of the bound
form or Db ~ 0.0, and by the same token, the concentration of the free form Df
~ 0.0 at saturation. Using equation 5a and 5b, we have the following:
F1L / F2L = [SfiDf + Sbi (0.0)] / [Sf2Df + Sb2 (0.0)] = Sn / Sf2
F1H / F2H = [Sn (0.0) + Sbi Db] / [Sf2 (0.0) + Sb2 Db] = Sfi / Sf2

[Rmin] •••93

[Rmax] ...9b

F2L / F2H = [Sn Df + Sbi (0.0)] / [S,2 (0.0) + Sb2 Db] = Sf2 / Sb2 [Sf]

9c

Note that in equation 9c, the term Df/Db reduces to 1 since at zero Ca2+, the
concentration of the free form is max and must equal to the concentration of
the bound form Db at saturation. Substituting the above values in equation
(7), we have;
[Ca2+]i = Kd {[R - R,ni„] / [Rmax - R]} Sf.....(10)
[Ca2+]i = concentration of intracellular Ca2+, Kd is the dissociation constant
and Sf is the scale factor.
Overall; Rmjn is monitored by simply measuring the I5io340 / Is-ioSSO ratio at zero
Ca2+, and Rmax by monitoring the l5io340 / I5io380 ratio at saturation. The Sf is
obtained from these two measurements by taking the ratio of lsio380 at zero Ca2+
to lsio380 at saturation. With these values we can calculate the concentration of
intracellular calcium from the measured fluorescence intensity using equation
(10).
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